Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
Page 45
Page 46
Page 47
Page 48
Page 49
Page 50
Page 51
Page 52
Page 53
Page 54
Page 55
Page 56
Page 57
Page 58
Page 59
Page 60
Page 61
Page 62
Page 63
Page 64
Page 65
Page 66
Page 67
Page 68
Page 69
Page 70
Page 71
Page 72
Page 73
Page 74
Page 75
Page 76
Page 77
Page 78
Page 79
Page 80
Page 81
Page 82
Page 83
Page 84
Annual Report 2014 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 Phone 61 8 6151 0700 Fax 61 8 6151 0701 QEII Medical Centre 6 Verdun St Nedlands WA 6009 PO Box 7214 Shenton Park Western Australia 6008 ABN 16 823 190 402 Connect with us at the Harry Perkins Institute of Medical Research Mostofthestunningfluorescentcellimagesdisplayedinthis publicationwerecreatedbyresearcherswhoenteredthe annualPerkinsphotographycompetitionin2014. Website Socialmedia www.facebook.comharryperkinsinstitute www.twitter.comperkinscomms www.linkedin.comcompanyharry-perkins-institute-of-medical-research 3 Contents About the Perkins 4 Chairmans Report 8 Directors Report 10 Board of Directors 12 2014 Highlights 15 Research at the Perkins Our Disease Focus 29 Cancer and Cell Biology 31 Cardiovascular Diabetes and Metabolism 43 Molecular Medicine and Ageing 47 Perkins Research Centres 55 Perkins Research Facilities 61 Community Engagement 67 Scientific Publications 72 Our Supporters 76 Financial Reports 78 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 4 AboutthePerkins Ourvision Ourmission Ourvalues The Perkins is a world leader in medical research delivering global improvements in human health. To conduct innovative research that translates into lasting health benefits. Respect Innovation Passion Collaboration Respect is at the core of our organisation. We treat our colleagues and everyone in our diverse community with honesty integrity and respect. We are a talented group of like-minded individuals at teh forefront of modern mediacl research using our creativity and the latest technology in our relentless quest for medical breakthroughs. We bring a passion and commitment to every aspect of our work. We recognise the power of working closely with each other and our collaborators to achieve the outstanding results for which we strive. Driving discovery delivering hope 5 Harrys vision and commitment to improving the lives of Western Australians led to the creation of the Western Australian Institute for Medical Research WAIMR in 1998. The respect in which he was held and his unrelenting drive to boost medical research in Western Australia were instrumental in bringing together The University of Western Australia and the Royal Perth and Sir Charles Gairdner hospitals as the founding partners. He also led the team which raised the funds for the establishment of the Institute. One of the major gifts was a 5 million donation from Wesfarmers. A farmer in the Bruce Rock area where he was born Harry Perkins went on to a distinguished business career culminating in 16 years as Chairman of Wesfarmers Limited. He died of cancer in 2002. Harry was one of those rare individuals who having identified a need went out and did something about it. The annual Harry Perkins Oration commemorates his great service to the people of Western Australia. The name in our logo is based on Harry Perkins actual signature. Ourname The Harry Perkins Institute of Medical Research was named in honour of our inaugural Chairman the late Harry Perkins AO who played a pivotal role in the creation of the Institute. HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 6 ORGANISATIONAL STRUCTURE FINANCE DIRECTOR Tony Spezzacatena SCIE CLIN P R P Ru OPERATIONS CHIEFOPERATING OFFICER John Fitzgerald FUNDRAISING DIRECTOR Lesley Hooper CA CE Research Support Executive Scientic Advisory Committee Research Support Teams 7 ENTIFIC HEAD SCIENTIFIC HEAD SCIENTIFIC HEAD NICAL HEAD CLINICAL HEAD CLINICAL HEAD Professor Peter Thompson Professor Phillipa Lamont Professor Andrew Redfern Professor Grant Morahan Professor Nigel Laing DIRECTOR Professor Peter Leedman Professor uth Ganss INTERNATIONAL LIAISON CLINICALTRIALS MOLECULAR MEDICINE ANDAGEING DIVISION CARDIOVASCULAR DISEASEAND DIABETESDIVISION ADVISOR Professor Graeme Hankey ANCERAND ELLBIOLOGY DIVISION Laboratories and Centres Senior Faculty DEPUTY DIRECTOR Professor Peter Thompson Board of Directors Professor Aleksandra Filipovskana SCIENTIFIC HEAD SCIENTIFIC HEAD SCIENTIFIC HEAD CLINICAL HEAD CLINICAL HEAD CLINICAL HEAD Professor Peter Thompson Professor Phillipa Lamont Professor Andrew Redfern Professor Grant Morahan Professor Nigel Laing DIRECTOR Professor Peter Leedman Professor Ruth Ganss INTERNATIONAL LIAISON CLINICALTRIALS MOLECULAR MEDICINE ANDAGEING DIVISION CARDIOVASCULAR DISEASEAND DIABETESDIVISION ADVISOR Professor Graeme Hankey CANCERAND CELLBIOLOGY DIVISION Laboratories and Centres Senior Faculty DEPUTY DIRECTOR Professor Peter Thompson Board of Directors Professor Aleksandra Filipovska HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 8 ChairmansReport Thank you for reading the 2014 Annual Report of the Harry Perkins Institute of Medical Research and for your support of its important work. Laurence Iffla Chairman Harry Perkins Institute of Medical Research The opening of the Perkins Nedlands building in March 2014 by the Prime Minister was a very special occasion. In the presence of many distinguished guests eminent scientists community leaders and supporters of medical research we dedicated this magnificent new research facility to the people who are themselves dedicated in the pursuit of medical research for the greater understanding of disease and ultimately for a healthier and brighter future for all of us. Researchers from the Institute and many other research organisations moved into the building over the year and the positive effect on morale and research was almost immediate. The fundamental principle of collaboration that the late Harry Perkins imbued in all of us has at last been given a wonderfully encouraging new environment. Another major change took place at the opening when we also farewelled inaugural and long-serving Institute Director Professor Peter Klinken who retired after nearly 15 years in the role. At the same time we welcomed Professor Peter Leedman as the new Director of the Perkins Institute. The former Deputy Director of the Institute Peter Leedman has taken up the position as Director with great enthusiasm and on behalf of the Board and staff of the Institute I thank him sincerely for his sheer hard work and fantastic dedication. Later in the year we held a very moving celebration of Peter Klinkens extraordinary 15 year plus career leading the Institute in the new McCusker Auditorium with many speakers giving their insights into Peters wonderful qualities and interests. The video message from son Christian from Europe on behalf of his family completed the surprise for Peter We are proud that Peter Klinken is our inaugural Perkins Senior Fellow and were delighted when he was appointed Chief Scientist of Western Australia in June It is fitting to recognise that Professor Peter Klinken and new Director Professor Peter Leedman had worked together for many years on the vision of the new buildings and the Institute has been fortunate to have such a seamless transfer between these two close colleagues. The Institutes past chairman and Harry Perkins successor in that role Dick Lester AM was Chair of both the Implementation Committee that represented the funding partners and the Project Control Groups which oversaw much of the building detail. Dick was tireless in his efforts for the Nedlands building and the new Perkins facility which was completed later in the year within the Fiona Stanley Hospital precinct. The planting of the Lester Oak in the gardens adjacent to the Nedlands Perkins building is a small token of our appreciation. My sincere thanks to the Board who have guided the Institutes affairs with great care and commitment over the past year and also to the dedicated staff and researchers at the Institute. It is an honour to work with you and on behalf of medical research. 9 We are looking forward to the future with great excitement and anticipation LARRYIFFLA 10 Ihopeyoushare myenthusiasmfor thisvisionofthePerkins andIinviteyoutojoinwith usonourjourneygoing forwardasweneedyour continuedsupportand involvementatalllevels PETERLEEDMAN HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 11 DirectorsReport Professor Peter Leedman Director Harry Perkins Institute of Medical Research In March 2014 the Prime Minister of Australia officially opened the doors of our north facility at Nedlands and on the same day I became the Director. As I told our guests on that occasion I felt I had just been given one of the best jobs in the world uniting my twin passions of science and medicine. I am both a scientist and a practicing physician. With my scientific hat on I am passionate about the Institute making new discoveries embracing and developing new technologies and fostering the careers of young scientists. With my physician hat on I am passionate about improving the health and care of my patients translating the innovations made at the laboratory bench into clinical outcomes and fostering the research careers of young medical doctors. As a doctor I have worked in the public health system for over 20 years. Not only has it grounded me it also gives me the opportunity to directly connect innovation and discovery made in the Perkins with advances in clinical trials and new treatments - connecting the bench to the bedside. Our new buildings are definitely examples of how big is beautiful We are now able to think big and be bold think outside the box and foster new local and global collaborations. On that note it is an incredibly exciting time to be involved in medical research because advances in technology are having a major impact on everything we do. For example we are using advanced technology to sequence parts of our genome at lightning speed and relating that information back to the patient and we are generating new therapies with much higher specificity than ever thought possible before embracing the concept of precision medicine which we hope will deliver medicines that are more effective with less side-effects. The Perkins has established three Divisions in the past year Cancer and Cell Biology Cardiovascular Disease and Diabetes and Molecular Medicine and Ageing. The Perkins is focusing on these diseases because they continue to take the lives of our loved ones our neighbours colleagues and friends - and because we believe we can make a difference. Within each Division we are working in multidisciplinary teams where our top scientists are working side by side with medically trained doctors pathologists biostatisticians clinical trials and bioinformatics experts who can crunch through the tsunami of data and make it clinically relevant. Collaboration within and across the Divisions is a core component of our success. We are actively recruiting new world-class scientists and clinicians to the Perkins who are being attracted to the environment which is one of cutting edge innovation mixed with passion collaboration and a focus on the translation of our discoveries into improving clinical outcomes. I hope you share my enthusiasm for this vision of the Perkins and I invite you to join with us on our journey going forward as we need your continued support and involvement at all levels. It is a pleasure to write my first Directors message in an annual report for the Harry Perkins Institute of Medical Research. HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 12 Mr Iffla has been Non-Executive Director since March 2005 and Chairman of the Board from 20 May 2009. He is a partner in the legal firm Iffla Wade and prior to that was a partner for 25 years with the national legal firm Mallesons Stephen Jaques. He practices primarily in the area of commercial property law State taxes and trusts and joint ventures. Mr Iffla is a non-executive Director of the Perron Group and is Chairman of not- for-profit body Future Living Trust Inc. He is a former member of the Council of Law Society of Western Australia and previously held the position of Treasurer at the Society. Dr Every joined the Board in April 2013. He is a Metallurgist by profession having completed his Bachelors Degree in 1968 and a Doctorate in 1971. In 2000 he was awarded a Centenary Medal and in 2012 was recognised as an Officer of the Order of Australia. His first role as a CEO of a listed company was as Chief Executive Officer of Steel Tube Holdings Limited in New Zealand from 1988-91 and then was appointed Managing Director and CEO of Tubemakers. He subsequently worked for BHP and held a number of senior roles before becoming President of BHP Steel in 1999. He took up the role of Managing Director and CEO of OneSteel in February 2000. He is now Chairman of Wesfarmers Limited and Chairman of Boral Limited as well as a Patron of Redkite. Dr Davis joined the Board in 2012. He is a Radiologist and Partner of Perth Radiological Clinic. He is a medical graduate of UWA a Member of the Royal College of Physicians UK and Fellow of the Australian and New Zealand College of Radiologists. He has clinical experience in Australia England and the USA including 14 years as a Consultant at Sir Charles Gairdner Hospital. Dr Davis was Chairman of Perth Radiological Clinic for 9 years. He has experience as a non executive director in England and Australia and is a Fellow of the Australian Institute of Company Directors. Professor Geelhoed the Chief Medical Officer of WA joined the Board in June 2013. He is a Paediatric Emergency Physician who received his qualifications at The University of Western Australia. Previously he was Director of the Emergency Department at Princess Margaret Hospital for 21 years. He is a federal and WA AMA Councillor Chairman of the Drug and Alcohol Organisation and is a member of the Healthway Board. He is a past President of the Australian Medical Association WA. Professor Geelhoeds main research interest lies in acute respiratory illness in children. Dr Bob Every AO Professor Gary Geelhoed BoardofDirectors Mr Laurence Iffla Chair Dr Stephen Davis 13 Mr Kessell joined the Board in August 2010. He was Executive General Manager Corporate Affairs at Wesfarmers Limited for 12 years retiring in 2008. Previously he worked as a journalist in Western Australia and Canberra and as a senior adviser to the Hon Fred Chaney and with Dr John Hewson Leader of the Federal Opposition. Mr Kessell has been a member of the Board of the West Australian Symphony Orchestra since June 2007. Dr Smyth joined the Board in 2013. She has over 30 years experience in the mineral and petroleum industries. She was Principal Geologist for BHP Minerals Limited and BHP-Utah Minerals Internationals Beenup Project Manager Manager Gas Market Development WA for BHP Petroleum and General Manager Corporate Affairs for Woodside Petroleum Limited. She has a Bachelor of Science from The University of Western Australia and an Applied Master of Science from McGill University in Montreal Canada. In 2008 she was awarded an Honorary Doctor of Letters from the University of Western Australia and in 2012 was elected as a Fellow of the Australian Academy of Technological Sciences and Engineering. She was the Chair of Toro Energy Limited for nine years before stepping down in 2015. She is the Chair of Scitech and the Diabetes Research Foundation of WA and a Director of Emeco Holdings Ltd. Mr Leonhardt has been a Non-Executive Director since 1998 and is responsible for the Perkins Finance Committee. He is an independent company director and advisor with extensive business financial and corporate experience. He is a Chartered Accountant former Senior Partner with PricewaterhouseCoopers and Managing Partner of Coopers Lybrand in Western Australia. He is Chairman of Carnarvon Petroleum and a non executive director of CTI Logistics Limited together with a number of private companies. He is also a member of the Cancer Research Trust. Mr Leonhardt is a member of a number of professional bodies including the Australian Institute of Company Directors of which he is a life member and a former State Councillor. Winthrop Professor John Challis joined the Board in June 2014 as proxy for the Vice Chancellor of The University of Western Australia. He commenced his position as Pro Vice-Chancellor for Health and Medical Research in February 2014 and holds the title of University Professor Emeritus at the University of Toronto and Adjunct Professor at the University of British Columbia and at Simon Fraser University. John completed his training at the University of Cambridge University of California San Diego and Harvard Medical School and held a Junior Research Fellowship at Wolfson College University of Oxford before moving to McGill University Montreal Canada. More recently he served as Chair of the Department of Physiology at the University of Toronto and later as Vice President Research and Associate Provost of that University. He was the inaugural Scientific Director of the Canadian Institutes for Health Research Institute of Human Development Child and Youth Health and served as President and CEO of the Michael Smith Foundation for Health Research in Vancouver BC. Dr Erica Smyth Winthrop Professor John Challis Mr Keith Kessell Mr Peter Leonhardt HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 14 Breastcancer cellsinteracting withtherapeutic nanoparticles byAnnabelSorolla Bardajifromthe LaboratoryofCancer Epigenetics. 15 New headquarters for Harry Perkins Institute of Medical Research 16 Collaborative environments for groundbreaking research 19 Surprise Thank you for Professor Peter Klinken 24 2014 Wesfarmers Hary Perkins Oration 25 Inaugural Weekend to End Womens Cancers 26 2014 Ride to Conquer Cancer 27 Awards for Research Excellence 28 2014Highlights HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 16 17 More than 400 guests including His Excellency the Governor and Mrs McCusker and Western Australian Health Minister Kim Hames were present for the ceremony held at the main entrance to the spectacular new 10-storey building which houses laboratories office spaces and clinical research areas. This facility is of the highest international standard said Professor Peter Klinken who was instrumental in obtaining funding for the QEII building as well as another facility in Murdoch. The Commonwealth contributed 70 million to the cost of the building and the State government paid 25 million which was matched by the University of Western Australia. Together Lotterywest and the McCusker and Perron Charitable Foundations provided a further 7 million. The Lions Eye Institute also provided vital support while the QEII Trust leased the land to the Institute. The Chairman of the Perkins Larry Iffla said the towering glass building was a visible sign of growth for the Institute which is also expanding in prominence. He said 200 medical researchers were already busy in the buildings laboratories and there was room to accommodate 750 scientists doctors and students. The opening ceremony also served as an official handover of the Directorship. Professor Peter Klinken who was Director of the Institute previously known as the Western Australian Institute for Medical Research WAIMR for close to 15 years handed over the role to Professor Peter Leedman and wished him well. NewHeadquartersforHarryPerkins InstituteofMedicalResearch The Australian Prime Minister the Hon. Tony Abbott MP officially opened the Harry Perkins Institute of Medical Researchs new 122 million flagship research facility at Nedlands in March. PETERLEEDMAN Wearenow abletothinkbig andbeboldthink outsidetheboxand fosternewandexciting collaborations Former Chairman Dick Lester was tireless in his efforts for the new building. HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 18 19 Collaborative environmentsfor groundbreaking research PERKINS NORTH Queen Elizabeth II Medical Centre Nedlands PERKINS SOUTH Fiona Stanley Hospital Murdoch 20 21 The facility was constructed by Doric and designed by Hames Sharley which was honoured at the Australian Institute of Architecture State Awards with the top award in the Public Architecture category and an Architecture Award for Interior Architecture. Hames Sharley Director James Edwards said that the Institutes dramatic departure from the orthodoxy of laboratory design set it apart from other medical research institutes. We proposed a radically different approach built around a central highly activated core with the laboratories running north to south with natural light on two sides said Mr Edwards. To walk between the offices and the laboratories researchers have to move through the centre which houses the meeting rooms lunch rooms lifts toilets and a striking chromosome-inspired stairway that spirals up the core of the building. Mr Edwards said the idea was that as researchers encountered each other in these central spaces relationships would build and ideas would be exchanged. As well as Perkins researchers the building includes levels devoted to research by the University of WA the Lions Eye Institute the Lung Institute of WA the Heart Research Institute and the Centre for Nursing Research. There are also stimulating exhibitions and educational opportunities for the public in the foyer and on the first level. Read the Community Engagement section in this report to learn more about the interactive areas in the Nedlands building. PerkinsNorth Queen Elizabeth II Medical Centre Nedlands Perkins researchers and support staff have moved into two custom-built research facilities including a 10-storey building in Nedlands which is the Institutes headquarters. 22 23 Also designed by architects Hames Sharley the 5-storey building was constructed by Brookfield Multiplex. The facility includes clinical research laboratory research health education academic offices and research office space all complementary to the clinical services planned for the adjacent Fiona Stanley tertiary teaching hospital. The new research building has the capacity to accommodate 360 medical researchers who also come from State Health research groups and UWA research groups together with UWA academic staff. It is located adjacent to the new Integrated Education Facility and the Pathwest facility. Hames Sharley Director James Edwards said the south building had been designed with its own identity that complemented the architecture of the hospital. Like the north building research and academic spaces are organised to break down barriers and promote collaboration he said. Offices are grouped with full height internal glass walls supporting strong visual connections between offices areas and the labs as well as permitting optimum natural light. This arrangement supports teams of varying size and maximises opportunities for contact between researchers. PerkinsSouth Fiona Stanley Hospital Murdoch The new Perkins South facility is prominently located at the entrance to the new Fiona Stanley Hospital in Murdoch. HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 24 Professor Peter Klinken who was Director of WAIMR from 1998 to 2000 then 2002 to 2014 when it was renamed the Harry Perkins Institute of Medical Research was surprised by the secretly organised thank you event in the McCusker Auditorium. As well as current and former colleagues Professor Klinken was joined by his family for the celebration of his Directorship. His son Christian sent his best wishes in a video message. Professor Klinkens many achievements over 20 years were detailed in stories by Mr Dick Lester AM former chair of WAIMRPerkins Mr John Poynton AM a friend involved in early fundraising Mr Keith Kessell Board member and connected through Wesfarmers Professor John Funder AO member of the Scientific Advisory Committee and long term friend Professor Alan Robson AO Former Vice Chancellor of UWA Dr Louise Winteringham from the Leukaemia Laboratory and new Perkins Director Professor Peter Leedman. Professor Klinken received a number of gifts from the Perkins including a book which is a pictorial history of his time as Director. The Institute has also named the science exhibition walkway on Level 1 of the Perkins North building KLINKEN WALK. Professor Klinken remains in the Perkins Leukaemia laboratory as well as working in his new State government advisory role as the Chief Scientist of WA. SurpriseThankyoufor ProfessorPeterKlinken There were reminiscences laughter and a few tears when the end of an important era was celebrated in December 2014. Left to right Professor Peter Leedman Mr Keith Kessell Mr Dick Lester AM Professor Peter Klinken Mr Larry Iffla Dr Louise Winteringham Professor John Funder AO Mr John Poynton AM. 25 2014Wesfarmers HarryPerkinsOration A renowned cardiologist Professor Jennings spoke about the latest medical research on the causes prevention and treatment of heart disease. Professor Jennings warned that Sitting is the new Smoking and said that sedentary lifestyles were contributing to heart attacks. He also updated the public audience on the latest medical research and treatments available for patients. The 2014 Oration also provided the ideal occasion for the announcement of a substantial philanthropic gift from Wesfarmers. The Chairman of the Harry Perkins Institute of Medical Research Laurence Iffla announced that Wesfarmers had donated 5 million to the Perkins to establish Western Australias first Professorial Chair in Womens Cancers. The 2014 Wesfarmers Harry Perkins Oration featured guest speaker Professor Garry Jennings AO Director and Chief Executive Officer of the Baker IDI Heart and Diabetes Institute. LARRYIFFLA This gift will enable the appointment of an outstanding scientist to lead the new Perkins Centre for Womens Cancer Research Wesfarmers Chairman Dr Bob Every AO with Professor Garry Jennings AO and Perkins Chairman Larry Iffla. HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 26 InauguralWeekendto EndWomensCancers An enthusiastic crowd of 845 women and men challenged themselves to the gruelling 60 kilometre walk over two days making it WAs largest ever fundraising walk for womens cancers. The funds have already been allocated to a newly established Centre for Womens Cancers which will focus on cancer prevention and detection as well as finding targeted and personalised treatments for womens cancers. Professor Pilar Blancafort told walkers that her team was determined to make a difference in cancers which often have a poor prognosis. My research aims to develop new methods to target cancers that are difficult to treat and associated with poor outcome such as triple negative breast cancers and serious ovarian cancers Professor Blancafort said. The successful and inspirational Weekend will be held again in 2015. TM Perths first Weekend to End Womens Cancers raised an impressive 2.2 million for breast and ovarian cancer research projects at the Harry Perkins Institute of Medical Research. 27 Participants in this years Sunsuper Ride to Conquer Cancer braved wet windy conditions to complete the 200 kilometre cycling event. The ride raised 5.2 million for cancer research projects at the Harry Perkins Institute of Medical Research. 1311 riders participated despite bad weather making the long ride even more challenging than previous years. This is the third annual Ride and Australias largest cycling fundraising event said Perkins Director Professor Peter Leedman who thanked the riders for their amazing fundraising efforts. Funds raised through The Ride ensure sustainability for our research along with supporting new cancer research projects purchasing new equipment and supporting our cancer research teams. Cancer is a leading cause of death in Australia with one in two Australian men and one in three Australian women diagnosed with cancer before the age of 85. The 2015 Ride will be held on the 17th and 18th of October with Mining and Civil Australia MACA taking over as title sponsor for the event. Register now at 2014RidetoConquerCancer Top fundraising team MACA raised 1.4 million for cancer research at the Perkins HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 28 Nigel Laing University of Western Australia Vice-Chancellors Senior Research Award. Nigel Laing UWA Excellence in Teaching Award Category Research Supervision. Ruth Ganss Cancer Council WA Cancer Researcher of the Year 2013 - awarded March 2014. Ruth Ganss UWA Excellence in Teaching Award Category Research Supervision. Evan Ingley Awarded the Inaugural Sock-it-to-Sarcoma Senior Research Fellowship. Aleksandra Filipovska Awarded the Merck Millipore Research Medal 2014. Aleksandra Filipovska The Vice Chancellors Mid-Career Excellence Award The University of Western Australia. AwardsforResearchExcellence Oliver Rackham Scopus Young Researcher Award Runner Up Elsevier. Kevin Pfleger The Endocrine Society of Australia Mid-Career Research Award. Osvaldo Almeida Government Employees Superannuation Board GESB Award for improved outcomes in Seniors Mental Health presented by the Mental Health Commission. Osvaldo Almeida Awarded the Royal Australian and New Zealand College of Psychiatrists Senior Research Award. Julian Heng Travelling Fellowship Asian Pacific Society for Neurochemistry Taiwan 2014. Archa Fox The Vice Chancellors Mid-Career Research Award The University of Western Australia. Vance Matthews Nominated for a University of Western Australia Faculty of Medicine Dentistry and Health Sciences Excellence in Teaching Award. Gina Ravenscroft UWA Vice Chancellors Early Career Investigator Research Award. Associate Professor Oliver Rackham Professor Nigel Laing Professor Ruth Ganss Dr Archa Fox byAnnaJohansson LaboratoryofVascular Biologyandstromal targeting. OurResearchNormalising pancreatic tumourvesselsto enhanceanti-tumour therapies 29 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2015 30 ResearchatthePerkins Ourdiseasefocus Perkins researchers focus on some of the major diseases that affect our community. In particular we focus on cancer and diabetes and we have an increasing investment in cardiovascular disease research. Topoisomerase IIandManp duringInterphase byJamesAllenfromthe LeukaemiaLaboratory Cancerand CellBiology 31 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 32 CancerEpigeneticsLaboratory Associate Professor Pilar Blancafort and her team joined the Harry Perkins Institute of Medical Research in 2014. Associate Professor Blancafort is a specialist in genome engineering and gene targeting and her laboratory has pioneered the development of engineered DNA binding proteins to modulate the epigenetic state of cancer cells and delivery strategies for tumour targeting in pre-clinical studies. Recently the Blancafort laboratory has also produced small mini-transcription factors or interference peptides able to block oncogenic transcription factors over expressed in specific breast cancer subtypes. The team has begun the generation of targeted nanoparticles to encapsulate the aforementioned agents in both human cells and tumour tissues in mice models. The overall goal of the laboratory is to bring these new agents in pre-clinical and Phase I trials for metastatic basal-like breast cancer. 2014 Highlights Laboratory Head Associate Professor Pilar Blancafort Benjamin Garcia-Bloj MD Research Associate Dr Annabel Sorolla Research Associate Rabab Rashwan MD PhD student Colette Moses PhD student Ciara Duffy Honours Student Moleshri Paliwal Research assistant Mahira Arooj PhD Student James Constantine Student Agustin Sgro Student Shreyas Thiruvengadam Honours Student Edina Wang PhD Student The Cancer Epigenetics Laboratory moved from the APHB school at UWA campus to the Harry Perkins Institute of Medical Research The laboratory published this year in the journals Oncogene Beltran AS et al and Nucleic Acids Research Grimmer MR et al Dr. Anabel Sorolla received a postdoctoral fellowship from the National Breast Cancer Foundation NBCF Novel targeted therapies for triple negative breast cancer based on the use of engineered nanoparticles We received an ARC grant in collaboration with Professor K.S. Iyer at the School of Chemistry and Biochemistry at UWA We received a Cancer Council Western Australia CCWA grant with Professor K.S. Iyer for engineering of interference peptides iPepsto target basal-like breast tumours Associate Professor Pilar Blancafort was invited to present her work at the Dana Farber Cancer Institute Harvard Medical School Associate Professor Pilar Blancafort was invited as plenary speaker at the FASEB Conference in Nassau Bahamas on genome engineering cutting edge research and applications. Associate Professor Pilar Blancafort was invited at the genome engineering conference in Melbourne. Perkins photo competition prize Dr. Anabel Sorolla 33 LaboratoryforCancerGeneRegulation The laboratory of Cancer Gene Regulation investigates how genes are turned on and off in cancer and a variety of other diseases. Specifically the group studies unusual sub-nuclear bodies termed paraspeckles and investigates their role in diseases as well as how these can be used as a model system for understanding oncogenic complexes. In 2014 the group published several findings of importance to the field. The first was an International study involving researchers from Japan Australia and France jointly led by Dr. Fox in which it was shown that paraspeckles use a new mechanism for controlling gene expression and that this is particularly relevant when cells are stressed. This paper was published in Molecular Biology of the Cell and involved PhD student Ruohan Li as well as Dr. Fox. Another study was a collaboration with a group in the US showing that paraspeckles and NEAT1 are highly upregulated in advanced aggressive prostate cancer and thus represent a new therapeutic target. This was published in Nature Communications and included Ruohan Li former post-doctoral Fellow Sven Hennig and Dr. Fox. The third major study was published in the Journal of the National Cancer Institute and was the first demonstration that a specific paraspeckle protein NONO is a key oncogene in the devastating childhood cancer neuroblastoma. This finding was a collaboration with Dr. Tao Liu of the Childrens Cancer Institute in NSW and represents an important new collaboration for Dr. Fox. 2014 Highlights Simon Kobelke Research Officer Ellen Fortini PhD student Ruohan Li PhD student Geraldine Kong RA Agata Sadowska RA Pei Wen Lee RA 2014 saw Dr. Fox honoured with the University of WA Vice Chancellors mid-career research award. Dr. Fox also presented her work with an oral presentation at the annual meeting of the RNA society Canada with over 1000 registrants. PhD student Ruohan Li travelled to the US to attend the Cold Spring Harbour Conference on RNA regulation and he also spoke at the Asian Conference on Transcription Melbourne VIC. Laboratory Head Dr Archa Fox HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 34 During 2014 we have established new collaborations with groups in Verona ItalyDresden Germany and New York USA to investigate the function of SFK enzymes in leukemia and normal blood cells. This was as a direct result of our publications in the journals Blood in late 2013 and Biochemical Journal in 2014 and our group giving invited presentation as well as one-on-one meetings with these collaborators. We have been successful in 2014 in attaining funding from Sock it to Sarcoma to continue our sarcoma research as well as from the Cancer Council of WA for our leukemia research and presented our research at national conferences including the Garvan Signalling Symposium Sydney. 2014 Highlights CellSignallingGroup Cancer cells have over active enzymes of the type called protein tyrosine kinases PTK that function as onoff switches to control cancer cell growth and malignancy. My team investigates the functions of a subtype of PTK known as Src Family kinases SFK. We have discovered new interactions and pathways that SFK enzymes regulate in leukemia and bone cancer sarcoma cells that influence their ability to survive and become invasive. We also study the effects of drugs that target the SFK enzymes on normal as well as cancerleukemia cells and have discovered that these drugs have significant effects on normal cell function that could explain some of their side effects. These drugs are starting to be trialed in several different cancers including sarcoma breast and prostate cancer and as with all such treatments resistance is likely to eventually occur. Consequently we are assessing the mechanisms that cancer cells of these types can acquire resistance to these drugs and identify potential alternative pathways that could then be targeted when resistance occurs. Laboratory Head Associate Professor Evan Ingley Dr. Janice Lam Research Associate Cindy Le Research Assistant Rachel Jones PhD Student Priya Muralldharan PhD Student Matt Lee International Student Internship Rebecca Shapiro International Student Internship Morgane Davies Summer Student Alex Discombe Summer Student 35 LaboratoryforCancerMedicine Our research focuses on the mechanisms that regulate hormone action in various cancers eg breast and prostate cancer as well as identifying and utilizing microRNAs as therapeutics in cancer. In the hormone action group the focus has been on nuclear receptors and their coregulators whilst in the microRNA group the focus has been on microRNA-7 miR-7 and miR-331. The two arms of the laboratory are linked by their common interest in RNA biology and applying these findings in a translational sense in preclinical animal models with a longer-term view towards therapeutic application. The Leedman team is driving translational studies using microRNAs to help fight cancer. The team from the Leedman laboratory is working on preclinical translational models of head and neck cerebral gliomas prostate and liver cancer. The Leedman team has also shown that another protein discovered in the laboratory SLIRP is a potent tumour suppressor in colorectal cancer. This results from analysis of human colorectal cancer tissue microarrays of over 1000 patients. Preclinical animal models are in progress with the SLIRP knock out mouse to evaluate if they can recapitulate the human scenario. This work was also funded from NHMRC and ongoing involves analysis of human colorectal cancer tissues for stem like cells and potential treatments directed at reducing colorectal cancer metastasis. Leedman is also part of a human breast cancer consortium that published works in 2014 that have identified new potential nuclear receptor targets in breast cancer. These papers identified several new nuclear receptors as playing key roles in breast cancer and has set up the foundation for exploration of several of those receptors in murine models of breast cancer in order to translate the findings towards potential targeted therapeutics. Several translational models of breast cancer are being explored in mice including the PyMT model of breast cancer. Dr Shane Colley Research Fellow Dr Andrew Woo MRF Fellow Dianne Beveridge Senior Research Officer Lisa Stuart Senior Research Officer Rikki Brown Graduate Research Assistant Michael Epis Research Officer Clarissa Ganda Graduate Research Assistant Jessica Horsham PhD student Felicity Kalinowski Research Officer Kirsty Richardson Senior Technician Animal House Larissa Wintle Research Assistant Laboratory Head Professor Peter Leedman HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 36 LeukaemiaResearchLaboratory There are a number of disorders associated with abnormal blood cell production. These include anaemias and cancers of the blood or leukaemias. Normal blood cells can be transformed into abnormal cells by genetic mutations ie changes to the DNA. One of the challenges in finding new treatments for Acute Myeloid Leukemia is that there are few common genetic mutations. Perhaps even more challenging is that often important genes become de-regulated due to mutations in the regions of DNA that control gene expression rather than the genes themselves. At the Perkins we are studying new ways that leukaemia genes are regulated in particular the role of gene enhancers and micro RNAs miRNA. MiRNAs are small pieces of RNA that can regulate gene expression by degrading the gene message before it can be translated into a protein. We have identified a number of key miRNAs that regulate blood cell development and these appear to be deregulated in leukaemia. Importantly miRNAs are now being trialed as a new form of treatment for some cancers. This work has been carried out as part of a large multinational collaboration called FANTOM5 and has resulted in two very high profile publications in Nature An atlas of active enhancers across human cell types and tissues and A promoter-level mammalian expression atlas. In another area of our research we along with four other groups around Australia have formed the Australian Diamond-Blackfan Anaemia DBA Research Collaborative. This group has pooled resources to work towards understanding the causes of this disease and to identify better treatments for children born with this type of anaemia. In the laboratory we have developed red blood cells that contain the mutated gene responsible for this disease. Using these cells we have been able to identify all the genes that are affected by this mutation. We are now testing each of these genes to determine which ones affect red blood cell development and therefore could be novel targets for new DBA therapies. Laboratory Head Dr Louise Winteringham Professor Peter Klinken Chief Scientist Ms Jennifer Beaumont Research Associate Mr James Allen PhD Student Ms Joanne van Vuuren PhD student Ms Karolina Gorsevski Honours Student 37 Professor George Yeohs Presidency of the Cancer Council of WA and being an invited speaker to the Asian Pacific Association for the Study of the Liver 12-14 March 2014 Brisbane. The laboratory also acquired a Droplet Digital PCR instrument. 2014 Highlights LiverDiseaseandCarcinogenesis Our objective is to realise the use of a liver progenitor cell LPC for cell therapy to treat liver disease. Currently organ transplant is the only successful solution to cure end-stage liver disease. Large numbers of mouse LPCs can be generated and they readily differentiate into functional hepatocytes in culture. They can be used to treat mouse models of liver disease. We have also produced LPCs from mouse embryonic stem cells. Their ability to differentiate is being evaluated. In the longer term our animal studies will be applied to human liver disease using human LPCs. Towards achieving this objective we have identified human LPCs in patients with liver disease. During long term maintenance of our LPC lines some lines have become cancerous. This highlights two important issues. First we have to be extremely cautious in using LPCs for any form of therapy as we have to ensure we do not cause cancer. Second if LPCs can give rise to cancer are they the source of liver cancer in patients with chronic liver disease These findings have led us to focus on the molecular changes that accompany the change in our LPCs from being non-tumorigenic to tumorigenic. Knowledge of these alterations will be valuable in identifying tumorigenic LPCs that are unsuitable for use in therapy and developing methods that avoid their transformation. This may also be useful for documenting changes that occur during liver cancer development in patients. Dr Luke Diepeveen Postdoctoral Research Fellow Dr Magda Ratajska Research Fellow Mr Ken Woo Graduate Research Assistant Ms Michel Watson Graduate Research Assistant Ms Sarah McSpadden PhD student Mr Adam Passman PhD student Ms Megan Finch PhD student Ms Robyn Strauss PhD student Mr Philip Hardy PhD student Ms Anne Kramer PhD student Mr Neil Andrewartha PhD student Laboratory Head Professor George Yeoh HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 38 2014 Highlights MitochondrialMedicineandBiology Mitochondria are microscopic energy producing machines that are found in all human cells. Mitochondria contain a small set of genes that must work properly to make the energy our bodies require for health. Defects in the expression of mitochondrial genes cause debilitating diseases for which there are currently no cures. We have identified several different disease causing mutations in human cells developed a complete new set of analyses to understand how these mutations cause disease and provide insights into possible treatments. We have developed several different models of mitochondrial disease in mice. Laboratory Head Professor Alesksandra Filipovska Dr Tara Richman Postdoctoral Scientist Dr Bharti Morar Research Associate Anne-Marie Shearwood Research Assistant Judith Ermer Research Assistant Giulia Rosetti Research Assistant Stefan Siira PhD student Kara Perks PhD student Peter Alfrich Honours student Nicola Ferreira Honours student We have designed new tools to regulate gene expression in mitochondria published in Nature Communications We have developed a mouse model of mitochondrial disease caused by a mutation that compromises protein synthesis and energy metabolism published in PLOS Genetics We have identified that estrogen can mediate the regulation of mitochondrial gene expression published in Molecular Endocrinology We have characterised a new protein with dual functions in mitochondria published in Nucleic Acids Research We have established diagnostic pipelines for the analyses of mutations in genes encoding mitochondrial proteins We have hosted the biannual national conference on mitochondrial research AussieMit2014 Prof Filipovska was awarded the Merck Medal that is given annually to an outstanding Australian biochemist or molecular biologist and she delivered the Merck Millipore Medal Lecture at the ComBio meeting in Canberra Prof Filipovska was awarded the Vice-Chancellors Mid Career Excellence Award We have been awarded NHMRC project grant funding to investigate the cause and pathology of mitochondrial diseases 39 Our work on making protein machines to control genes was published in Nature Communications. We hosted the National Mitochondrial Conference AussieMit in collaboration with Professor Filipovskas lab. AProf Oliver Rackham was awarded the Cancer Council WA Research Fellowship. Our work was presented at prestigious international conferences including NanoBio and FEBS-EMBO Paris as invited talks. 2014 Highlights SyntheticBiologyandDrugDiscovery Research in this group focuses on re-engineering bacteria and yeast for use as microscopic drug factories. Large high quality libraries of new drugs are absolutely essential resources to find new medicines. However their use is restricted to a few pharmaceutical giants. We are engineering cells to make a wide variety of drug-like molecules providing a unique drug discovery resource accessible to almost any scientific laboratory. As each cell can make a different molecule of interest billions of different potential drugs could be produced in a single tube. This technology provides an opportunity to put the future of drug discovery in the hands of the wider scientific community and provides new tools for Australian industries. Furthermore these synthetic biology studies will provide insights into the fundamental biological processes that are essential for all living cells. Recent findings from this group have produced proteins designed to enable the therapeutic manipulation of mammalian gene expression. These engineered proteins can be made to control the expression of any gene of interest and the lab is now working to target genes that cause cancer and mitochondrial disease. Tiong Sun Chia PhD Student Moira Hibbs Research Assistant Chris Kleemann Work Experience Student James Lingford Research Assistant Anima Poudyal Research Assistant Sue Powell Research Assistant Doctor Muhammad Fazril bin Mohamad Razif Visiting Scientist Louis Scott PhD Student Christopher Wallis PhD Student Lachlan Wheeler PhD Student Laboratory Head Associate Professor Oliver Rackham HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 40 Targeteddrugdeliveryimagingandtherapy We focus on developing strategies to specifically target diseases such as cancer and atherosclerosis for diagnostic imaging and local therapeutic interventions. A major challenge to detect and treat chronic inflammatory diseases such as cancer and atherosclerosis i.e. hardening of the arteries due to fat accumulation is to effectively deliver contrast agents and therapeutics into the pathological tissues whilst avoiding off-target binding and consequent cytotoxic effects. Our team focuses on developing tools and strategies to target the microenvironment of cancers i.e. breast carcinoma insulinoma and hepatocellular carcinoma and atherosclerotic plaques for imaging and therapy. We have recently characterised a number of small molecules i.e. peptides that specifically bind to the abnormal cellular and non-cellular components in cancers and atherosclerotic lesions including blood vessels macrophages and extracellular matrix. These tumour and plaque specific peptides can then be used as a drug delivery agent into the pathological tissues. Using chemical coupling bioengineering and nanotechnology approaches we have developed imaging contrast agents and therapeutics fused with these targeting peptides for in vivo applications in pre-clinical models of cancers and atherosclerosis as well in human cancers and vascular diseases. Laboratory Head Assistant Professor Juliana Hamzah Meenu Chopra Research Assistant Jenny Wang Research Assistant Yen Ling Yeow Research Assistant We have been awarded NHMRC and Cancer Council WA project grant funding to develop nano-delivery and therapeutic reagents for arterial disease and cancer. Jenny Wang biologist University of Melbourne and Meenu Chopra nanotechnologistchemist University of Science and Technology Haryana India have been recruited to join our team. We established collaboration with Dr. Farah Abdul Aziz Director Breast Centre Sir Charles Gairdner Hospital and Dr. Greg Sterrett PathWest to investigate the translational application of our reagents in human breast cancer. 2014 Highlights 41 In 2014 we discovered that pre-existing maternal cardiovascular problems increase the risk for preeclampsia which challenges the current dogma that preeclampsia is caused by poor placentation. In addition we discovered new regulatory pathways and potential new drug targets for a currently incurable disease which warrants clinical evaluation. In 2014 Ruth Ganss was awarded the UWA Faculty of Medicine Dentistry and Health Sciences teaching award for Excellence in Research Supervision. This Award followed NHMRCfellowship success of early career researchers in the team and demonstrates the labs strong commitment to mentoring. 2014 Highlights VascularBiologyandstromaltargeting The Vascular Biology and Stromal Targeting Laboratory focuses on blood vessels as a crucial component of normal tissue function and in disease. We study the role of blood vessels in cancer and importantly design new strategiesdrugs to manipulate blood vessels within the cancerous tissue for improved anti-cancer therapy. This treatment also enables better access of immune cells into malignant tissue which is particularly interesting with the arrival of immunotherapy in the clinic. We have developed intellectual property rights on one lead compound in 2014 which opens highly translational opportunities. Ruth Ganss has been awarded the inaugural Cancer Researcher of the Year 2014 Cancer Council WA Award for her novel studies and breakthroughs in the field. Our laboratory also studies blood vessels and regulatory pathways in other important vascular diseases such as hypertension and pregnancy-related complications for instance preeclampsia which manifests in high blood pressure in the mother and placental abnormalities. The cause of these pregnancy complications is so far unknown but represents a serious health problem for the mother and the child. Dr. Anna Johansson Research Associate Dr. Jacky Li Research Associate Dr. Niloufer Johansen Research Associate Dr. Bo He Research Officer Dr. Jennifer Burchell Research Officer Dr. Vasyl Holobotovskyy Research Officer Mr. Yee Seng Chong PhD Student Ms. Devina Lakhiani Research Assistant In 2014 we discovered that pre-existing maternal cardiovascular problems increase the risk for preeclampsia which challenges the current dogma that preeclampsia is caused by poor placentation. In addition we discovered new regulatory pathways and potential new drug targets for a currently incurable disease which warrants clinical evaluation. In 2014 Ruth Ganss was awarded the UWA Faculty of Medicine Dentistry and Health Sciences teaching award for Excellence in Research Supervision. This Award followed NHMRCfellowship success of early career researchers in the team and demonstrates the labs strong commitment to mentoring. 2014 Highlights Laboratory Head Scientific Leader of Perkins Cancer and Cell Biology Division Professor Ruth Ganss HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 42 Glomerulus oneofthefiltering unitsofthekidney byDrAronChakera LaboratoryofTranslational RenalResearch Cardiovascular Diabetesand metabolism 43 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 44 Diabetes At The Centre for Diabetes Research our research is aimed at understanding and preventing diabetes and its complications. Diabetes is recognized as a major public health problem and is Australias fifth national health priority area. Diabetes is characterized by increased blood sugar levels and has two major forms Type 1 diabetes which results from the persons own immune system destroying the insulin-producing cells and Type 2 diabetes which results from the persons growing inability to respond normally to insulin. Both forms of diabetes are caused by complex interactions between many genes and environmental factors. Our particular focus is on the genetics of Type 1 diabetes. We are developing systems genetics technologies which integrate multiple levels of data with underlying genetic information allowing the definition of networks of interacting genes. These methods have allowed us to define genetic signatures that indicate a persons risk of developing diabetic complications and other disease outcomes. Our group is part of the world-wide Type 1 Diabetes Genetics Consortium and led collaborative networks across Australia and the Asia-Pacific region in assembling resources to identify and characterise the genes which affect the risk of developing Type 1 diabetes. We also study animal models of type 2 diabetes and diabetes complications. Our work has resulted in the identification of genes affecting each form of diabetes in both humans and mice. We are now investigating ways that we can restore the ability to produce insulin by developing stem cell treatments. Finally we established the world-leading genetic resource The Gene Mine which enables rapid discovery of genes for complex traits and development of new animal models of disease. The Gene Mine is particularly useful for making systems genetics discoveries. The Centre for Diabetes Research gratefully acknowledges the support of the Diabetes Research Foundation of WA. Director of Centre for Diabetes Research Professor Grant Morahan AProf Fang-Xu Jiang Dr Sylvia Young Research Fellow Lois Balmer Senior Research Assistant Emily Chivers Student Mailby De Bastiani Student International Jonathan Grasko PhD student Emma Jamieson Research Assistant Munish Mehta Senior Bioinformatics Officer Quang Nguyen Research Assistant Natalia Portini Student International Ramesh Ram Research Associate Lakshini Weerasekera PhD student Dr Kevin Li Research Associate 2014 Highlights Developed methods to define subtypes of Type 1 diabetes and Type 2 diabetes Developed methods to predict a persons risk of disease outcomes such as surviving melanoma having a heart attack or stroke or developing diabetic complications. Performed proof-of-principle demonstration that The Gene Mine can provide rapid identification of genes mediating complex traits. 45 TranslationalRenalResearch One in six Australians has impaired kidney function with one in three at risk of developing kidney disease. In most cases kidney disease is asymptomatic until almost all function is lost making early diagnosis challenging. For people who progress to end stage more than 2000 people annually outcomes are worse than for many cancers. The Translational Renal Research group in focused on improving outcomes for patients with renal diseases by translating advances in basic science from the bench to the bedside and developing ways to enhance the care of patients with renal diseases. Research is the laboratory is looking at the immune system and how it is affected by immunosuppression. As infectious diseases are common problems in renal patients by studying host responses to pathogens we are defining factors that may predict the likelihood of disease and responses to treatment. Current areas of interest are 1. Host responses to common viruses in particular CMV and BKV after renal transplantation 2. Interactions between bacteria and peritoneal mesothelial cells 3. The antimicrobial properties of short chain fatty acids Current clinical projects include 1. Early treatment of post-transplant diabetes mellitus with DPP-4 inhibitors 2. Economic evaluation of an assisted peritoneal dialysis program 3. The impact of CMV reactivation on clinical outcomes following renal transplantation Christine Carson Senior Post-Doc Researcher Amanda McGuire Research Officer Laboratory Head Dr Aron Chakera 2014 Highlights Successful SHRAC funding for the implementation of a pilot assisted peritoneal dialysis program in Western Australia Funding from the Diabetes Foundation of Western Australia to investigate the utility of DPP4 inhibitors in reducing post- transplant diabetes mellitus HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 46 MetabolicDysfunction Laboratory Head Assistant Professor Vance Matthews Prostate cancer is the most prevalent cancer in men and is a significant burden in Australia and other western countries. The molecular mechanisms that promote prostate cancer progression remain to be fully investigated. The metalloproteinase known as ADAM28 was first identified on lymphoid cells. Our collaborator Yasunori Okada in Japan Keio University is an expert in the functionality of ADAM28 and has previously demonstrated that ADAM28 activity plays a critical role in the pathogenesis of breast cancer head and neck cancer and non-small lung cancer. One of the major substrates of ADAM28 is Insulin-like growth factor binding protein-3 IGFBP-3. This finding may have major clinical relevance for prostate cancer as IGFBP-3 cleavage may result in liberation of IGF-1 which is a potent growth factor for prostate cancer cells. We are also investigating the role of another metalloproteinase known as ADAM19 in human prostate cancer. Over nutrition promotes obesity which greatly increases the risk of type 2 diabetes and cardiovascular disease. It is generally acknowledged that current therapeutic strategies to arrest Type 2 diabetes have failed. It is of prime importance to develop new human therapeutics to alleviate Type 2 diabetes. Work from our group and others have implicated a number of soluble factors such as the pro-inflammatory cytokine TNF- in the aetiology of obesity and insulin resistance. Activation of the metalloproteinase tumor necrosis factor- converting enzyme TACE or ADAM17 is critically required for the release of TNF-into the circulation. Excitingly we recently gained data implicating a relatively newly discovered metalloproteinase known as ADAM19 in inflammation obesity and type 2 diabetes. Published studies have highlighted that ADAM19 may cleave TNF-and alpha-2 macroglobulin which increases the half-life of TNF-. Our current project aims to determine whether the metalloproteinase ADAM19 may promote inflammation and insulin resistance in vitro and in vivo. Numerous studies have already illustrated that reducing TACE activity effectively reduces obesity induced insulin resistance. Our study will further support that metalloproteinase inhibition is a potential therapeutic target for anti-obesity agents in humans. 47 Ourpatentapplicationentitledmethodsforgenerationofmaturedinsulin- secretingcellswassubmittedforaninternationalexamination. AninvitedreviewwaspublishedinStemCellsDevelopmenttosummarisethe stateandcontroversyofpancreaticstemcellsJiangMorahan. JiangF.-X.2014PancreaticStemCellsRemainingUnresolved.Kingdom ofSaudiArabiaStemCellsinScienceandMedicineSymposium.Riyadh KSAInvitedkeynotespeaker JiangF.-X.2014Generatingneurogenin3-expressingisletprogenitorskey towardsfunctionalinsulin-secretingcells.KingdomofSaudiArabiaStemCells inScienceandMedicineSymposium.RiyadhKSAInvitedkeynotespeaker JiangF.-X.2014Generatingfunctionalinsulin-secretingcellsfromislet progenitorsforadiabetesregenerativetherapy.UCL-UWA-HMGUCollaborative ResearchNetwork.LondonUKInvitedspeaker. JiangF.-X.2014Pancreas-specificDeletionofBmpr1aImpairsglucose homeostasisLinkedtoOverexpressionofTph1.AustralianDiabetesSociety AnnualMeetingMelbourne.Speakerselectedfromabstracts JiangF.-X.2014DiabetesregenerativestrategiesinPerkinsUWA. 3rdShanghai JiaotongTranslationalMedicineSymposium.Perthinvitedspeaker. 2014 Highlights 1. Understand molecular mechanisms by which the insulin-secreting cells become fully functional and matured. 2. Understand molecular mechanisms why the insulin-secreting cells loss function and lead to diabetes 3. Identify regulators that stimulate restore function of failed insulin-secreting cells and therefore may be used to cure diabetes. 4. Establish models that we can use to understand molecular mechanisms of failure of insulin-secreting cells. IsletCellDevelopmentProgram Associate Professor Hongtu Li Visiting scientist Associate Professor Wei Wang Visiting scientist Mr Abrahan John PhD student Ms Farhana Ruma PhD student Laboratory Head Associate Professor Fang-Xu Jiang HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 48 MolecularMedicine andAgeing Fetalbrain cellsstainedin threecolours byAssociateProfessorJulian HengLaboratoryforBrain GrowthandDisease 49 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 50 MolecularEndocrinologyandPharmacology The Laboratory for Molecular Endocrinology and Pharmacology is studying how different molecules particularly hormones bind to our cells and transmit distinct signals into them. This communication is absolutely essential for coordination of our cells tissues and organs. We have known for many years that the receptors for these molecules have evolved to respond with great precision and consequently represent exceptional targets for pharmaceuticals. However we now realise that in addition to precision receptor combinations termed heteromers provide enormous potential for signal integration. Could it be that many medication side-effects are due to our lack of understanding this integration Can we use this knowledge to develop better pharmaceuticals Our laboratory is developing and successfully applying our world-leading patented technologies to answer these questions including the Receptor-Heteromer Investigation Technology Receptor-HIT. This research is being translated through the Perkins spin- out company Dimerix Bioscience Ltd of which Laboratory Head Associate Professor Kevin Pfleger is Chief Scientific Advisor. The laboratory published two papers in Frontiers in Endocrinology and a third in the British Journal of Pharmacology in 2014. Work of the laboratory was presented at conferences and seminars locally across Australia Adelaide Melbourne and Sydney and internationally Leicester Nottingham and London in the UK Madison Boston and Houston in the US. Kevin Pfleger was awarded an NHMRC Career Development Fellowship Level 2 two NHMRC project grants as Chief Investigator B and the prestigious Endocrine Society of Australia Mid-Career Research Award 2014. Dr Carl White was awarded an NHMRC Early Career CJ Martin Fellowship to be supervised by Kevin Pfleger at the Perkins and globally-recognised pharmacologist Professor Stephen Hill at The University of Nottingham. Professor Hill carried out his sabbatical at the Perkins in 2013-2014 as a Raine Visiting Professor and has since been appointed as an Adjunct Professor of The University of Western Australia. Laboratory Head Associate Professor Kevin Pfleger Dr Renae Barr Research Fellow Dr Carl White Research Associate Ruth Seeber Research Officer Heng See Graduate Research Assistant Rekhati Abhayawardana Graduate Research Assistant Elizabeth Johnstone PhD Student Professor Stephen Hill Adjunct Professor Gwen Pfleger Laboratory Manager 51 MolecularEndocrinologyCellularRegulation Professor Tom Ratajczaks team continues to investigate hormone action with a translational bias in several different paradigms including prostate cancer and speech defects as well as disorders of calcium homeostasis and bone disease. The work presents a great example of clinically relevant translational bench-to-bedside research in action. The Ratajczak lab is credited with the discovery of cyclophilin 40 CyP40 an estrogen receptor-associated protein involved in modulating steroid receptor function. In recent work by the team supported by a New Concept Grant from the Prostate Cancer Foundation of Australia increased expression of CyP40 in androgen receptor-positive prostate cancer cells was shown to upregulate expression of androgen-regulated genes. In an exciting new development collaborators at the Melbourne Brain Centre have identified a mutation in the CyP40 PPID gene that is strongly associated with a severe speech disorder in a large Australian family. With the support of a grant-in-aid the Ratajczak team has begun investigations aimed at understanding the causal relationship between the mutation and the speech disorder leading to better treatment outcomes for affected individuals. Dr Bryan Ward Research Associate Sarah Rea Research Fellow Carmel Cluning Research Officer Melanie Sultana Research Assistant Steroid Hormone Action Calcium Receptor and Mutations in Clinical Bone Disease The Ratajczak lab continues to characterise new mutations in the calcium receptor that are responsible for gain-of- function and loss-of-function abnormalities. The team provides mutation detection and diagnosis for the State of WA and is actively working on the functional biology of specific mutations so that the information gained can be translated back in clinical practice. The Ratajczak team is also focused on genetic studies of genes involved in the development of Pagets disease of bone PDB. Pagets disease is a chronic and progressive disorder affecting around 3 of Australians in which bone is excessively remodelled. Mutations in the sequestosome 1 SQSTM1 gene have been identified and the lab continues to sequence additional patients looking for new mutations. In addition via one of their collaborators using genome- wide approaches they have identified novel proteins associated with PDB e.g. CSF1 encoding macrophage colony- stimulating factor M-CSF NUP205 encoding nucleoporin TM7SF4 encoding dendritic cell-specific transmembrane protein DC-STAMP OPTN encoding optineurin RIN3 encoding Ras and Rab interactor 3 PML encoding promyelocytic leukaemia protein PML. Laboratory Head Professor Tom Ratajczak HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 52 NeurogeneticDiseasesGroup TheNeurogeneticDiseasesGrouphasfivethemestoitsresearch 1 Disease gene discovery finding genes which when they are mutated cause genetic diseases. 2 Functional genomics proving that a novel variant in a gene is in fact disease- causing 3 Development of therapies for selected neurogenetic diseases. 4 Development of better molecular diagnostic tools to provide more patients with a diagnosis 5 Research into the prevention of genetic diseases through newborn screening and preconception carrier screening. The Group had 15 publications in 2014 including two new disease genes LMOD3 and SPEG which were shown to be associated with severe including paralysis before birth congenital myopathies nemaline myopathy and centronuclear myopathy respectively. In 2014 the Group was awarded the largest Australian National Health and Medical Research Council Project Grant won by a group at the University of Western Australia. The grant for 2.4m over the five years 2015-2019 is for the Groups disease gene discovery research. The grant is funding a collaboration between the Perkins Group the Institute for Neuromuscular Research Westmead Sydney Murdoch Childrens Research Institute and the Monash University zebrafish facility both in Melbourne and the Broad Institute in Boston one of the worlds foremost genomics research institutes. Professor Laing was awarded the University of Western Australia Vice Chancellors Senior Research Award and Dr Gianina Ravenscroft a Junior Vice Chancellors Research Award. The next generation sequencing diagnostic researched by PhD Student Kyle Yau has now been implemented in the Neurogenetics Unit PathWest Diagnostic Genomics for over a year and is proving highly successful. This has reinforced the Neurogenetics Unit as the National Referral Centre for Neuromuscular molecular diagnostics. Members of the Group gave overseas invited presentations in Heidelberg Germany Nice in France Shenzhen in China and many of the Group presented at the World Muscle Society Annual Congress in Berlin. Group Leader NHMRC Principal Research Fellow Professor Nigel Laing Dr Kristen Nowak Deputy Group Leader ARC Future Fellow Dr Gina Ravenscroft Pathophysiology Theme Leader NHMRC Early Career Fellow Dr Rachael Duff Post-doc Ms Elyshia McNamara Laboratory Manager Mr Royston Ong Graduate Research Assistant Mr Kyle Yau PhD Student Ms Emily Todd PhD Student Mr Jordan Boutilier PhD Student Dr Macarena Cabrera-Serrano PhD Student Ms Klair Bayley Masters Student Ms Sarah Beecroft Honours Student 53 2014 Highlights BrainGrowthandDisease In August 2014 Associate Professor Julian Heng established the Brain Growth and Disease Laboratory at the Perkins. The goal of his research is to understand the genetic causes of childhood brain disorders such as intellectual disability epilepsy and autism spectrum disorder. This work will enable health practitioners and clinicians to improve the diagnosis and treatment of children with these conditions. Associate Professor Julian Heng is a former Science graduate of the University of Western Australia and has trained all over the world to develop novel experimental approaches to investigate the fundamental basis of brain development and disease. In 2014 his research on the functions for a novel brain disease-causing gene in humans Ngo et al Human Molecular Genetics 2014 was the focus of media attention by the Guardian UK and the Herald Sun Melbourne Australia. Associate Professor Heng is working with local National and International researchers to define the genetics of brain development with a long-term goal to identify the key molecular mechanisms which underpin the formation of brain circuits as well as their functionality. Linh Ngo Graduate Research Assistant Hayley Cullen Graduate Research Assistant Isabel Hemming Summer Vacation Student 2014 Travelling Fellowship Asian Pacific Society for Neurochemistry Taiwan. 2014 Highlights Laboratory Head Associate Professor Julian Heng HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 54 Heartcolony ofmelanoma cells byRikkiBrown KirkbrideMelanoma Centre Research Centres 55 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 56 The Kirkbride Melanoma was established following the death of Scott Kirkbride whose life was cut short by melanoma when he was just 27 years old. KirkbrideMelanomaCentre formerly Scott Kirkbride Melanoma Centre SKMRC New Look Kirkbride December 2014 saw the launch of the SKMRC branding makeover which included a new name and refreshed logo. Melanoma Research The Kirkbride Centre opened applications in 2014 for the inaugural Kirkbride Professor of Melanoma Research. During the year the Kirkbride Centre maintained its translational research projects linked to a microRNA molecule known as miR-7. The molecule shows great potential as a treatment to stop melanoma spreading as it is able to reduce the processes that promote the growth of melanoma. Research investigating predictors of a patients response to therapies and disease recurrence also continued. Discovery Grants Program The Kirkbride Melanoma Centre established Discovery Priming Grants for basic melanoma research five years ago. To strengthen the work being undertaken the Suncorp Melanoma Research Discovery Grant program commenced in 2011. Both programs provided 75000 annually for research projects with the aim of generating suitable preliminary data to support future grant applications to national funding bodies such as the National Health and Medical Research Council NHMRC. The success of the grants programs has been demonstrated by all recipients publishing melanoma research findings answering some of the complex questions about this disease. 2014 Highlights Kirkbride Melanoma Centre Committee Mr Graeme Morgan Chairman Mrs Yvonne Kirkbride Mr Nick Kirkbride Professor Peter Leedman Medical Director Professor Peter Klinken Mr Rob Scott Professor John Thompson Mr Peter Toll Mr Grant Vernon Scientific Advisory Committee Professor Nick Hayward Professor Graham Mann Professor Grant McArthur 57 2014 Discovery Grants recipients DrKeithGilesRikkiBrownandProfessorPeterLeedmanHarryPerkinsInstituteofMedicalResearch AnewapproachtopreventingthespreadofmelanomaEvaluationofanewmicroRNA-basedapproachtoblockmelanoma metastasiswhichaimedtoidentifywhetherthismicroRNAmoleculeisapotentialtreatmentformetastaticmelanoma. Professor Prue Hart and Dr Shelley Gorman Telethon Kids Institute How sun exposure links with melanoma initiation and progression A novel immune component of the susceptibility formula for melanoma which aimed to elucidate the sunlight-initiated process whereby immune cells in the bone marrow are altered and become less competent in recognising and destroying melanoma. Western Australian Melanoma Health Study WAMHS This study was established by the Kirkbride Centre 2006 and aimed to invite all patients in Western Australia who had been diagnosed with invasive melanoma to participate. Blood samples histo-pathology data and information on exposure and other risk factors were collected from 1643 consenting patients to form an extensive population-based database and linked bio-specimen resource. This resource has been used widely by melanoma researchers around Australia resulting in several significant journal publications. The study is due to reopen in late 2015. National Melanoma Conference After the success of Australias inaugural national melanoma conference which was hosted in Perth by the Kirkbride Melanoma Centre in 2012 the centre ran a second national conference in 2014. The conference held on the 10th and 11th October presented scientific information about developments in melanoma research such as recent breakthroughs as well as challenges in the detection and treatment of melanoma. The National Melanoma Conferences have provided a high benchmark for future meetings and have been accepted wholeheartedly by the melanoma community as an event to attend on the biennial meeting calendar. Melanoma Community Breakfast 2014 As part of the 2nd National Melanoma Conference in October 2014 the Kirkbride Melanoma Centre in conjunction with melanoma WA hosted a forum for the general public. The informal session provided an opportunity for guests to speak to distinguished melanoma experts from around Australia and the USA. Discussions included the latest treatments new research clinical trials and the importance of support networks. Annual Community Forum Every year for the benefit of the community the Kirkbride Centre hosts an informative and interactive forum presented by a specialist in melanoma. On 26th March 2014 Dr Mark Shackleton Head of the Melanoma Research Laboratory at the Peter MacCallum Cancer Centre in Melbourne spoke about the need for investment in basic research as it is an area that provides quantum leaps in treatments for patients. He also discussed the new immune therapies soon to be reported and the critical importance of continuing research into this aggressive cancer. Themissionofthe KirkbrideCentreisto establishWesternAustralia asaworldleaderinbasicand clinicalmelanomaresearch byprovidingcrucial breakthroughsforimproved diagnosisandtreatment ofmelanoma. 58 CentreforClinicalResearchinEmergencyMedicine The Centre for Clinical Research in Emergency Medicine CCREM is a unique unit established at Royal Perth Hospital Perth Western Australia that brings together clinical staff working in the Emergency Department ED and laboratory scientists using immunological and molecular biological techniques. CCREM investigates a number of conditions within the spectrum of disease treated in Emergency Departments. 2014 was notable for the continued success of the pneumothorax study an international multicentre clinical trial coordinated by CCREM of interventional vs conservative management of primary spontaneous pneumothorax. This study was successful in obtaining NHMRC funding and recruitment has now passed the halfway mark to the target sample size. Previous work by CCREM was acknowledged by two awards at the annual scientific meeting of the Australasian College for Emergency Medicine the John Gilroy Potts Award best paper published in emergency medicine for our anaphylaxis paper published in the Journal of Allergy and Clinical Immunology and the Emergency Care Institute best paper on best practice pain management in the Emergency Department. Sepsis and critical illness continues to be a focus of CCREM. Our Critical Illness and Shock study has enrolled over 1000 patients. We now have a rich cohort of samples for study. This lead to AProf Stephen Macdonald being successful in being awarded the inaugural New Investigator Grant from the Australasian College for Emergency Medicine Research Foundation to examine sepsis biomarkers. This is also invaluable for our new PhD student. CCREM continues to pursue extensive clinical collaborations. AProf Glenn Arendts is leading our work in the study of geriatric syndromes especially admission avoidance for elderly patients and others with complex needs. Prof Yusuf Nagree continues his work investigating chest pain in the Emergency Department. Professor Simon Brown Professor Daniel Fatovich AProfessor Glenn Arendts AProfessor Shelley Stone AProfessor Stephen MacDonald Professor Yusuf Nagree Miss Abbie Creamer PhD student Dr Lisa Stone PhD student 59 NeurotraumaResearchProgram The Neurotrauma Research Program NRP supports scientific and clinical research projects which are aimed at improving functional recovery from injuries to the central nervous system neurotrauma as well as projects that help the community avoid trauma to the nervous system from road accidents. The NRP receives funding from the Road Safety Council and private donations and has supported scientists in Western Australia to become prominent internationally in the field of neurotrauma research. We support and bring together basic scientists and clinicians in collaborative research programs that are improving the lives of people affected by neurotrauma in Western Australia. This year has seen further very successful outcomes from NRP funded research projects and Western Australia continues to be a significant contributor to global neurotrauma research. AProfessor Bruno Meloni has found that certain peptides administered to rats can reduce brain damage after a stroke and future studies will move towards clinical trials. The incidence of stroke in our community is increasing and this is a significant breakthrough as there are currently no neuroprotective treatments available. Professor Dunlops team have received funding to join an Australia-wide trial looking at hypothermia and decompression surgery to improve outcomes following spinal cord injury. This project has the potential to reduce the number of people in Australia who face a future of permanent paralysis. A major cause of brain and spinal injury is road trauma modifying driver behaviour is an important tool in reducing the incidence of neurotrauma. AProfessor Troy Visser has received funding to develop simulated driving programs for younger and older drivers which improve alertness and reduce response to distractions. The NRP also recognises the importance of training our next generation of neuroscientists and we have supported several PhD students during 2014. The NRP provides travel bursaries for students to attend the Australasian Neuroscience Society ANS annual scientific meeting as well as funding prizes for young researchers presenting at the Symposium for Western Australian Neurosciences. Ourvisionis thatthrough promotingexcellence inneurotraumaresearch nobodywillhavetolive withpermanentdisability fromtraumatic brainorspinal cordinjury. Chairman Professor Bryant Stokes Executive Committee Professor Peter Leedman Professor Barry Marshall the Hon Liz Behjat MLC Mr Peter Sarich Mr Anton Zappelli. 2014 Executive Officers Ms Louise Goodes Ms Vidya Findlay HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 60 Better health in mid-life and beyond WesternAustralianCentreforHealthandAgeing The development of a culturally acceptable depression screening tool for remote living Indigenous Australians. This tool has been instrumental in improving the lives and health of older Indigenous Australians and has been pivotal in bringing about a positive change. As with our dementia screening tool the Kimberley Indigenous Cognitive Assessment KICA designed at the Centre there has been huge interest in this research internationally and around Australia. Research has confirmed that people with a severe mental disorder who reach older age have a lower life expectancy compared to their peers. These results demonstrate that it is never too late to intervene. Intervening at this late stage of life would make a marked difference to the quality of life of people living with mental illness and would decrease the long term costs associated with their medical care. Improving current anti-depressant medication treatment by supplementing medication with B vitamins improves response to treatment. Our researchers have proven that using vitamin B12 and folate every day for at least a year can enhance the effectiveness of anti- depressant treatment and helps prevent relapse of major depression in middle-aged and older adults Alargegroupofoldermenhavebeenhelping ourresearchunlockthesecretsonhowto livetoaripeoldageandalongthewayare challenginglong-heldbeliefsaboutageing. ThisgroupofWesternAustralianmenhave periodicallysharedtheirhealthstatisticsblood samplesandhealthcheckswithourresearcherforovernineteenyears. In199612000menagedbetween65-80yearswere recruitedfromtheelectoralrolltojointhislandmarkstudy. Overtheyearsmanyimportantfindingshavecomefromcombining thedatawithdatafromtheWAdatalinkagesystem. Someofthefindingsof2014include Biomarkers have been identified that make some people more vulnerable to depression as they age. This is an important finding as medical professionals might be able to do things to address this. They found that physical activity was another way to reduce the risk of depression. Older adults who were physically active not only have a lower risk of dying over time but they have a lower risk of depression and better quality of life. Men who became active during the Health in Men study reaped the rewards indicating that it is never too late to start. Similar associations were also found between physical activity and cognitive function. Our researchers are also looking at ways to postpone further memory decline in people living with Alzheimers disease through cognitive exercise and physical activity. We expect to release some preliminary data next year. Older adults benefit from medication de-prescription. Our researchers have proved the idea that withdrawal from one selected drug over a two month period has improved the health and quality of life of older adults. Our researchers are now running a large randomised control trial across 2 states to examine the effects of measured medication withdrawal in frail people who reside in residential care facilities. Awards Our research director and leading psychiatrist in old age Professor Osvaldo Almeida has been recognised for his research excellence with a prestigious Royal Australian and New Zealand College of Psychiatrists Senior Research Award. This is only the second time a Western Australian has received the award in the awards 35 year history. Professor Osvaldo Almeida was also awarded the Mental Health Commissions GESB Award for his contribution to improving outcomes in Seniors Mental Health. Up-and-coming Indigenous health and ageing research Ms Roslyn Malay was awarded the Australian Association of Gerontology WA bursary to attend the AAG conference in Adelaide. She is a member of the Aboriginal and Torres Strait Islander Ageing Advisory Group and looks forward to making a bigger impact on improving the lives of older Indigenous people who live in remote areas of Australia in particular the Kimberley. The Western Australian Centre for Health and Ageing WACHA is dedicated to improving health in mid-life and beyond. Our research focuses on finding new treatments to prevent disease and discovering cures for disabling diseases such as dementia depression and frailty. Research fellow Dr Zo Hyde Professor Osvaldo Almeida Research Director WACHA and Chair of Geriatric Psychiatry UWA Professor Leon Flicker WACHA Director and Chair of Geriatric Medicine UWA 2014 Research Highlights Research Facilities Vascular networksin pancreatic tumours byDrAnnaJohansson LaboratoryofVascular Biologyandstromal targeting 61 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 62 LinearClinicalResearch Linear Clinical Research Ltd is the Perkins award-winning flagship in translational clinical research. Linear has completed almost 100 studies and in 2014 was very active the unit being full virtually all of the time. 23 new clinical trials commenced in 2014 Over 500 healthy volunteers and over 100 patients enrolled in clinical trials across 10 different therapeutic areas Winner of WA Industry Export Award Healthcare and Biotechnology 2013 2014 Linear strengthened its position in the Asian market by conducting its foremost First Time in Human Phase 1 Study for both a Japanese and Chinese Sponsor. Reached 35 full time employees. 2014 Highlights CEO of Linear Clinical Research Dr Janakan Krishnarajah Chairman of the Board of Linear Clinical Research Professor Peter Leedman 63 Therapeutic Area Sponsor Origin Client Type Study Phase Anti-Infective 0 1 2 3 4 5 6 Central Nervous System Endochrinology Hepatology Metabolic Infectious Disease Nephrology Oncology Respiratory Rheumatology USA 65 Australia 13 China 9 Japan 9 New Zealand 4 New 65 Repeat 35 Phase I Other 35 Phase II 22 Phase I First Time in Human 35 Phase III 8 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 64 MonoclonalAntibodyFacility Led by Kathy Davern the Institutes monoclonal antibody facility provides a service for Researchers Clinicians and Commercial groups across the nation and overseas. The Facility generates top-class serum-based products including novel antivenom agents and multiple monoclonal antibodies for use in a variety of clinical and preclinical arenas. The Davern lab continues to generate multiple antibodies during 2014 to a range of target antigens including human Hepatitis C virus mesothelioma human carcinomas and molecules involved in muscular dystrophies taste cancers diabetes and lung disease. Laboratory Head Kathleen Davern Pauline Van Eeden Laboratory Services Manager Jessica Lonsdale Research Assistant Victor Last Technical Assistant Annette Thompson Technical Assistant Michael Bradley Technical Assistant Rod Quinn Research Support 65 AustralianCancerResearchFoundation CancerImagingFacility In 2014 the Perkins established a high end preclinical imaging facility the ACRF Cancer Imaging Facility CIF at its main headquarters on the QEII Medical Centre campus at Nedlands. This preclinical equipment is essential in the fight against human cancer by helping experts in the field move towards earlier disease detection prevention strategies and assessment of the efficacy of new cancer treatments. The preclinical MRI PETCT and SPECTCT scanners in the CIF are non-invasive high resolution monitoring tools that are smaller versions of human imaging equipment allowing researchers to examine tumour development in pre- clinical models of cancer and determine effective forms of treatment. Investigating tumours in these models is a critical bridge between discoveries in the laboratory and the development of therapeutics to treat cancer patients. The ACRF Cancer Imaging Facility at the Perkins offers unparalleled access to an imaging platform unsurpassed in Australia. Importantly researchers in WA now have the capacity for longitudinal studies in preclinical models previously not possible. With the ability to undertake research on a par with our European counterparts supported by a professional team of clinical and bio-resource experts we are well placed to drive ground breaking cancer research. The Australian Cancer Research Foundation funded State Cancer Imaging Facility was fully operative in its temporary home in B Block QEIIMC from January to October 2014 when it closed to move to its new state-of-the-art purpose built premises within the Perkins Bioresources unit. Imaging technologists from Nuclear Medicine and Radiology were appointed on a part-time basis to establish the facility and ensure the machines were fully commissioned and functional. The Facility comprises a suite of cutting edge technologies unique within Australia. The Facility will allow sophisticated imaging to be performed for the first time in WA and will provide a major advance for translational research in the State. World-class images from several projects have already been acquired. Some of the early work has focused on mesothelioma. The outcome of this work has been to fast-track the translation of basic research in this area into clinical models of disease. The ACRF CIF imaging staff last week completed some advanced imaging applications in PET and MRI on site with the imaging specialist from France. WAs ground breaking state facility HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 66 Imagebyastudent visitingtheLotterywest BioDiscoveryCentre showingmineralcrystals underthe microscope. Community Engagement 67 68 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 69 ExhibitionareasatthePerkins The Harry Perkins Institute of Medical Research aims to demystify medical research by demonstrating to members of the community how our talented scientists are working to prevent treat and cure diseases. Community engagement programs allow visitors to experience science through customised programs in a purpose-built laboratory setting using high-tech equipment and guided by real medical researchers. The centre uses a variety of strategies to engage visitors including guided tours of the facility presentations by renowned Perkins researchers and practical workshops. Colourful exhibition spaces were designed by Freeman Ryan Design and funded by Lotterywest. A tour of the buildings exhibition spaces offers a visual history of medical research from the discovery of penicillin to a chronicle of Australian Nobel Prize Laureates. Three 4-metre tall double-sided LED banners display colourful microscopic cell images with an accompanying interactive iPad app describing the research involved in creating the image. Two huge male and female MRI scans are on display in the foyer with two LCD monitors moving across the scans and stopping on sections of the body to describe related research. There are also public seminars held in the evenings and meeting rooms which can be hired by the community include the 250 seat McCusker Auditorium a 100 seat seminar room and a 70 seat Lotterywest Community Resource room. Customised programs were developed for the following groups in 2014 Community groups eg. Lions Probus Participants from local major fundraising events the Ride to Conquer Cancer and the Weekend to End Womens Cancers Corporate groups for team building research-based activities Secondary school students Welcoming the community Most Western Australians have been touched by at least one of the serious diseases afflicting the community cancers diabetes heart disease and stroke. However few understand how the mutations in genes cause these diseases. Three 4-metre tall double-sided LED banners display colourful microscopic cell images with an accompanying interactive iPad app describing the research involved in creating the image. HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 70 LotterywestBioDiscoveryCentre With the vision to develop and enhance health literacy in the Western Australian community the Centre provides hands-on interactive experiences. The activities explore the intricacies of our most challenging human diseases such as cancer diabetes cardiovascular and neuromuscular diseases. The Lotterywest BioDiscovery Centre Manager Pauline Charman has recruited a dynamic team of talented medical researchers including Honours and PhD students from within the Harry Perkins Institute of Medical Research to help visitors with activities that are run in both a wet lab laboratory environment and a dry lab Community Resources Room. Customised programs have been developed for the following groups. 1. Community groups eg. Rotary Lions Probus 2. Participants from local major fundraising events the Ride to Conquer Cancer and the Weekend to End Womens Cancers 3. Corporate groups for team building research-based activities 4. Upper primary and secondary science students Visitors to the laboratory are immersed in a fully interactive experience which reveal how our scientists work with molecules that arent visible to the naked eye. This includes being taught how to extract DNA look at cells under a microscope and use the technical tools of a medical research scientist. The Next Gen School program is linked to the new Australian Curriculum requirements. These high-tech activities are designed to illustrate and provide real life applications of new science content that cannot be duplicated in a classroom. School students from rural and metropolitan WA have experienced the latest biotechnology including techniques to amplify genes staining and imaging cancer cells under the guidance of scientists. The use of iPads to document aspects of the activities in an e-journal was also a feature including streaming images to the iPad from a specialist microscope. A specialist STEM Science Technology Engineering and Mathematics focused course known as Perkins Profs Academy offers a special medical research framework for bright sciencemaths students. Visitors to the PC2 laboratory use advanced technology not available for public use anywhere else in Western Australia. The new Lotterywest BioDiscovery Centre at the Harry Perkins Institute of Medical Research is successfully increasing community awareness about the importance of medical research. 71 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 72 ScientificPublications Authors Macdonald S.P.J. Stone S.F. Neil C.L. Van Eeden P.E. Fatovich D.M. Arendts G. Brown S.G.A. Boyle T. Fritschi L. Tabatabaei S.M. Ringwald K. Heyworth J.S. Li Kwok Cheong J.D. Croft K.D. Henry P.D. Matthews V. Hodgson J.M. Ward N.C. Stasinska A. Heyworth J. Reid A. Callan A. Odland J.T. Trong Duong P. Van Ho Q. Hinwood A. Mooranian A. Negrulj R. Chen-Tan N. Al-Sallami H.S. Fang Z. Mukkur T.K. Mikov M. Golocorbin-Kon S. Fakhoury M. Watts G.F. Matthews V. Arfuso F. Al-Salami H. Fisher S.A. Cleaver A. Lakhiani D.D. Khong A. Connor T. Wylie B. Lesterhuis W.J. Robinson B.W.S. Lake R.A. Mooranian A. Negrulj R. Al-Sallami H.S. Fang Z. Mikov M. Golocorbin-Kon S. Fakhoury M. Watts G.F. Matthews V. Arfuso F. Lambros A. Al-Salami H. Robinson C. Alfonso H. Woo S. Olsen N. Bill Musk A.W. Robinson B.W.S. Nowak A.K. Lake R.A. Fox A.H. Gunawardena D. Tresham J. Hardie M. Phillips M. Wylie E. Agrawal P.B. Pierson C.R. Joshi M. Liu X. Ravenscroft G. Moghadaszadeh B. Talabere T. Viola M. Swanson L.C. Halilolu G. Talim B. Yau K.S. Allcock R.J.N. Laing N.G. Perrella M.A. Beggs A.H. Robinson C. Alfonso H. Woo S. Walsh A. Olsen N. Musk A.W. Robinson B.W.S. Nowak A.K. Lake R.A. Garg A. ORourke J. Long C. Doering J. Ravenscroft G. Bezprozvannaya S. Nelson B.R. Beetz N. Li L. Chen S. Laing N.G. Grange R.W. Bassel-Duby R. Olson E.N. Brown S.A. Viola H.M. Adams A.M. Davies S.M.K. Fletcher S. Filipovska A. Hool L.C. Liu P.Y. Erriquez D. Marshall G.M. Tee A.E. Polly P. Wong M. Liu B. Bell J.L. Zhang X.D. Milazzo G. Cheung B.B. Fox A. Swarbrick A. Httelmaier S. Kavallaris M. Perini G. Mattick J.S. Dinger M.E. Liu T. Mullins R.J. Brown S.G.A. McQualter J.L. Anthony D. Bozinovski S. Prele C.M. Laurent G.J. Isbister G.K. Page C.B. Buckley N.A. Fatovich D.M. Pascu O. MacDonald S.P.J. Calver L.A. Brown S.G.A. Stone S.F. Bosco A. Jones A. Cotterell C.L. Van Eeden P.E. Arendts G. Fatovich D.M. Brown S.G.A. Kalinowski F.C. Brown R.A.M. Ganda C. Giles K.M. Epis M.R. Horsham J. Leedman P.J. Finsterer J. Stllberger C. Brandau O. Laccone F. Bichler K. Laing N.G. Finch M.L. Marquardt J.U. Yeoh G.C. Callus B.A. Sim M. Dawson B. Landers G.J. Swinkels D.W. Tjalsma H. Wiegerinck E.T. Trinder D. Peeling P. Lesterhuis W.J. Bosco A. Lake R.A. Goh L.G.H. Dhaliwal S.S. Welborn T.A. Thompson P.L. Maycock B.R. Kerr D.A. Lee A.H. Bertolatti D. Clark K.M. Naheed R. Coorey R. Della P.R. Needhamsen M. White R.B. Giles K.M. Dunlop S.A. Thomas M.G. Lynch B.M. Boyle T. Daly A. Pollard C.M. Phillips M. Binns C.W. Humbert C. Silbermann F. Morar B. Parisot M. Zarhrate M. Masson C. Tores F. Blanchet P. Perez M.-J. Petrov Y. Khau Van Kien P. Roume J. Leroy B. Gribouval O. Kalaydjieva L. Heidet L. Salomon R. Antignac C. Benmerah A. Saunier S. Jeanpierre C. North K.N. Wang C.H. Clarke N. Jungbluth H. Vainzof M. Dowling J.J. Amburgey K. Quijano-Roy S. Beggs A.H. Sewry C. Laing N.G. Bnnemann C.G. Aloysius A. Apkon S. Bellini J. Bertini E. Biancalana V. Birnkrant D. Bushby K. Connolly A.M. Estournet-Mathiaud B. Ferreiro A. Fitzgerald D. Florence J.M. Richard Gee P.T. Giannetti J.G. Glanzman A. Goebel H. Guillet M. Hofmeister B. Labeit S. Laporte J. Little D. Kemp J. Koumbourlis A.C. Main M. Matthews D. Morrison L.A. Munns C. Muntoni F. Navarro C. Panitch H. Pelin K. Rose K. Santiago M.T. Schroth M.K. Sejersen T. Simonds A. da Silva H.C. Rinsky L. Romero N. Schochet P. Schuler P.M. Shapiro F. Storhaug K. Wallgren-Pettersson C. Wallis C. Weiss H. Yuan N. Robinson C. Alfonso H. Woo S. Olsen N. Musk A.W.B. Robinson B.W.S. Nowak A.K. Lake R.A. Campbell N.R.C. Appel L.J. Cappuccio F.P. Correa-Rotter R. Hankey G.J. Lackland D.T. Macgregor G. Neal B. Niebylski M.L. Webster J. Willis K.J. Woodward M. Richman T.R. Rackham O. Filipovska A. Slavova-Azmanova N.S. Kucera N. Louw A. Satiaputra J. Handoko A. Singer P. Stone L. McCarthy D.J. Klinken S.P. Hibbs M.L. Ingley E. Goode A. Long J.E. Shaw B. Ralston S.H. Visconti M.R. Gianfrancesco F. Esposito T. Gennari L. Merlotti D. Rendina D. Rea S.L. Sultana M. Searle M.S. Layfield R. Hankey G.J. Stevens S.R. Piccini J.P. Lokhnygina Y. Mahaffey K.W. Halperin J.L. Patel M.R. Breithardt G. Singer D.E. Becker R.C. Berkowitz S.D. Paolini J.F. Nessel C.C. Hacke W. Fox K.A.A. Califf R.M. Yuen M. Sandaradura S.A. Dowling J.J. Kostyukova A.S. Moroz N. Quinlan K.G. Lehtokari V.-L. Ravenscroft G. Todd E.J. Ceyhan-Birsoy O. Gokhin D.S. Maluenda J. Lek M. Nolent F. Pappas C.T. Novak S.M. DAmico A. Malfatti E. Thomas B.P. Gabriel S.B. Gupta N. Daly M.J. Ilkovski B. Houweling P.J. Davidson A.E. Swanson L.C. Brownstein C.A. Gupta V.A. Medne L. Shannon P. Martin N. Bick D.P. Flisberg A. Holmberg E. Van Den Bergh P. Lapunzina P. Waddell L.B. Sloboda D.D. Bertini E. Chitayat D. Telfer W.R. Laquerrire A. Gregorio C.C. Ottenheijm C.A.C. Bnnemann C.G. Pelin K. Beggs A.H. Hayashi Y.K. Romero N.B. Laing N.G. Nishino I. Wallgren-Pettersson C. Melki J. Fowler V.M. MacArthur D.G. North K.N. Clarke N.F. MacTiernan A. Fritschi L. Slevin T. Jalleh G. Donovan R. Heyworth J. Hankey G.J. Brown S.G.A. Ball E.L. Macdonald S.P.J. Wright C. Mcd Taylor D. Ram R. Mehta M. Balmer L. Gatti D.M. Morahan G. Lamont P.J. Wallefeld W. Hilton-Jones D. Udd B. Argov Z. Barboi A.C. Bonneman C. Boycott K.M. Bushby K. Connolly A.M. Davies N. Beggs A.H. Cox G.F. Dastgir J. Dechene E.T. Gooding R. Jungbluth H. Muelas N. Palmio J. Penttil S. Schmedding E. Suominen T. Straub V. Staples C. Van den Bergh P.Y.K. Vilchez J.J. Wagner K.R. Wheeler P.G. Wraige E. Laing N.G. Larcombe A.N. Phan J.A. Kicic A. Perks K.L. Mead-Hunter R. Mullins B.J. Richman T.R. Davies S.M.K. Shearwood A.-M.J. Ermer J.A. Scott L.H. Hibbs M.E. Rackham O. Filipovska A. 73 Title Publication Sustained elevation of resistin NGAL and IL-8 are associated with severe sepsisseptic shock in the emergency department PLoS ONE Smoking alcohol diabetes obesity socioeconomic status and the risk of colorectal cancer in a population-based casecontrol study Cancer Causes and Control Green coffee polyphenols do not attenuate features of the metabolic syndrome and improve endothelial function in mice fed a high fat diet Archives of Biochemistry and Biophysics Polybrominated diphenyl ether PBDE concentrations in plasma of pregnant women from Western Australia Science of the Total Environment Microencapsulation as a novel delivery method for the potential antidiabetic drug Probucol Drug Design Development and Therapy Neoadjuvant anti-tumor vaccination prior to surgery enhances survival Journal of Translational Medicine Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes AAPS PharmSciTech Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced Lung Cancer malignant mesothelioma Evidence from an animal model and a human cohort The noncoding RNA revolution International Journal of Biochemistry and Cell Biology Suspicious mammographic parenchymal abnormalities that are occult at ultrasonography Journal of Medical Imaging and Radiation Oncology SPEG interacts with myotubularin and its deficiency causes centronuclear myopathy with dilated cardiomyopathy American Journal of Human Genetics Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans PLoS ONE KLHL40 deficiency destabilizes thin filament proteins and promotes Nemaline myopathy Journal of Clinical Investigation Fluid resuscitation for people with sepsis Its time to challenge our basic assumptions BMJ Online Impaired functional communication between the L-type calcium channel and Proceedings of the National Academy of Sciences of the United States mitochondria contributes to metabolic inhibition in the mdx heart of America Effects of a novel long noncoding RNA lncUSMycN on N-Myc expression and Journal of the National Cancer Institute neuroblastoma progression Ant venom immunotherapy in Australia The unmet need Medical Journal of Australia Harnessing the potential of lung stem cells for regenerative medicine International Journal of Biochemistry and Cell Biology Randomized Controlled Trial of Intravenous Antivenom Versus Placebo for Latrodectism Annals of Emergency Medicine The Second Redback Antivenom Evaluation RAVE-II Study Genomic responses during acute human anaphylaxis are characterized by upregulation of innate inflammatory gene networks PLoS ONE microRNA-7 A tumor suppressor miRNA with therapeutic potential International Journal of Biochemistry and Cell Biology Novel MYH7 mutation associated with mild myopathy but life-threatening ventricular arrhythmias and noncompaction International Journal of Cardiology Regulation of microRNAs and their role in liver development regeneration and disease International Journal of Biochemistry and Cell Biology A seven day running training period increases basal urinary hepcidin levels as compared to cycling Journal of the International Society of Sports Nutrition Comment on Drug discovery Turning the titanic Science Translational Medicine Cardiovascular disease risk score prediction models for women and its applicability to Asians International Journal of Womens Health Regulation of human PAX6 expression by miR-7 Evolutionary Bioinformatics Distinguishing sedentary from inactive implications for meta-analyses British Journal of Cancer Benefits barriers and enablers of breastfeeding Factor analysis of population PLoS ONE perceptions in Western Australia Integrin alpha 8 recessive mutations are responsible for bilateral renal agenesis in humans American Journal of Human Genetics Approach to the diagnosis of congenital myopathies Neuromuscular Disorders Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma Evidence from an animal model and a human cohort Lung Cancer A Call for Quality Research on Salt Intake and Health From the World Hypertension League and Supporting Organizations Journal of Clinical Hypertension Mitochondria Unusual features of the mammalian mitoribosome International Journal of Biochemistry and Cell Biology Lyn kinase plays important roles in erythroid expansion maturation and erythropoietin receptor signalling by regulating inhibitory signalling pathways that control survival Biochemical Journal Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function Biochimica et Biophysica Acta - Molecular Basis of Disease Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban The rivaroxaban once daily oral direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation Stroke Leiomodin-dysfunction results in thin filament disorganization and nemaline myopathy Journal of Clinical Investigation Public perceptions of cancer risk factors A Western Australian study Health Promotion Journal of Australia Intracranial hemorrhage and novel anticoagulants for atrial fibrillation What have we learned Current Cardiology Reports Spontaneous pneumothorax a multicentre retrospective analysis of emergency treatment complications and outcomes Internal Medicine Journal Rapid identification of major-effect genes using the collaborative cross Genetics Novel Mutations Widen the Phenotypic Spectrum of Slow Skeletal-Cardiac Myosin MYH7 Distal Myopathy Human Mutation Route of exposure alters inflammation and lung function responses to diesel exhaust Inhalation Toxicology A bifunctional protein regulates mitochondrial protein synthesis Nucleic Acids Research HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 74 ScientificPublications Authors Hankey G.J. Lacey B. Ivanov I.S. Azmanov D.N. Ivanova M.B. Chamova T. Pacheva I.H. Panova M.V. Song S. Morar B. Yordanova R.V. Galabova F.K. Sotkova I.G. Linev A.J. Bitchev S. Shearwood A.M.J. Kancheva D. Gabrikova D. Karcagi V. Guergueltcheva V. Geneva I.E. Bozhinova V. Stoyanova V.K. Kremensky I. Jordanova A. Savov A. Horvath R. Brown M.A. Tournev I. Filipovska A. Kalaydjieva L. Forrest A.R.R. Kawaji H. Rehli M. Baillie J.K. De Hoon M.J.L. Haberle V. Lassmann T. Kulakovskiy I.V. Lizio M. Itoh M. Andersson R. Mungall C.J. Meehan T.F. Schmeier S. Bertin N. Jrgensen M. Dimont E. Arner E. Schmidl C. Schaefer U. Medvedeva Y.A. Plessy C. Vitezic M. Severin J. Semple C.A. Ishizu Y. Young R.S. Francescatto M. Altschuler I.A. Albanese D. Altschule G.M. Arakawa T. Archer J.A.C. Arner P. Babina M. Rennie S. Balwierz P.J. Beckhouse A.G. Pradhan-Bhatt S. Blake J.A. Blumenthal A. Bodega B. Bonetti A. Briggs J. Brombacher F. Burroughs A.M. Califano A. Cannistraci C.V. Carbajo D. Chen Y. Chierici M. Ciani Y. Clevers H.C. Dalla E. Davis C.A. Detmar M. Diehl A.D. Dohi T. Drabls F. Edge A.S.B. Edinger M. Ekwall K. Endoh M. Enomoto H. Fagiolini M. Fairbairn L. Fang H. Farach-Carson M.C. Faulkner G.J. Favorov A.V. Fisher M.E. Frith M.C. Fujita R. Fukuda S. Furlanello C. Furuno M. Furusawa J.-I. Geijtenbeek T.B. Gibson A.P. Gingeras T. Goldowitz D. Gough J. Guhl S. Guler R. Gustincich S. Ha T.J. Hamaguchi M. Hara M. Harbers M. Harshbarger J. Hasegawa A. Hasegawa Y. Hashimoto T. Herlyn M. Hitchens K.J. Sui S.J.H. Hofmann O.M. Hoof I. Hori F. Huminiecki L. Iida K. Ikawa T. Jankovic B.R. Jia H. Joshi A. Jurman G. Kaczkowski B. Kai C. Kaida K. Kaiho A. Kajiyama K. Kanamori-Katayama M. Kasianov A.S. Kasukawa T. Katayama S. Kato S. Kawaguchi S. Kawamoto H. Kawamura Y.I. Kawashima T. Kempfle J.S. Kenna T.J. Kere J. Khachigian L.M. Kitamura T. Klinken S.P. Knox A.J. Kojima M. Kojima S. Kondo N. Koseki H. Koyasu S. Krampitz S. Kubosaki A. Kwon A.T. Laros J.F.J. Lee W. Lennartsson A. Li K. Lilje B. Lipovich L. Mackay-sim A. Manabe R.-I. Mar J.C. Marchand B. Mathelier A. Mejhert N. Meynert A. Mizuno Y. De Morais D.A.L. Morikawa H. Morimoto M. Moro K. Motakis E. Motohashi H. Mummery C.L. Murata M. Nagao-Sato S. Nakachi Y. Nakahara F. Nakamura T. Nakamura Y. Nakazato K. Van Nimwegen E. Ninomiya N. Nishiyori H. Noma S. Nozaki T. Ogishima S. Ohkura N. Ohmiya H. Ohno H. Ohshima M. Okada-Hatakeyama M. Okazaki Y. Orlando V. Ovchinnikov D.A. Pain A. Passier R. Patrikakis M. Persson H. Piazza S. Prendergast J.G.D. Rackham O.J.L. Ramilowski J.A. Rashid M. Ravasi T. Rizzu P. Roncador M. Roy S. Rye M.B. Saijyo E. Sajantila A. Saka A. Sakaguchi S. Sakai M. Sato H. Satoh H. Savvi S. Saxena A. Schneider C. Schultes E.A. Schulze-Tanzil G.G. Schwegmann A. Sengstag T. Sheng G. Shimoji H. Shimoni Y. Shin J.W. Simon C. Sugiyama D. Sugiyama T. Suzuki M. Suzuki N. Swoboda R.K. T Hoen P.A.C. Tagami M. Tagami N.T. Takai J. Tanaka H. Tatsukawa H. Tatum Z. Thompson M. Toyoda H. Toyoda T. Valen E. Van De Wetering M. Van Den Berg L.M. Verardo R. Vijayan D. Vorontsov I.E. Wasserman W.W. Watanabe S. Wells C.A. Winteringham L.N. Wolvetang E. Wood E.J. Yamaguchi Y. Yamamoto M. Yoneda M. Yonekura Y. Yoshida S. Zabierowski S.E. Zhang P.G. Zhao X. Zucchelli S. Summers K.M. Suzuki H. Daub C.O. Kawai J. Heutink P. Hide W. Freeman T.C. Lenhard B. Bajic L.V.B. Taylor M.S. Makeev V.J. Sandelin A. Hume D.A. Carninci P. Hayashizaki Y. Ayoub M.A. Trebaux J. Vallaghe J. Charrier-Savournin F. Al-Hosaini K. Moya A.G. Pin J.-P. Pfleger K.D.G. Trinquet E. Geldenhuys S. Hart P.H. Endersby R. Jacoby P. Feelisch M. Weller R.B. Matthews V. Gorman S. Stone S.F. Phillips E.J. Wiese M.D. Heddle R.J. Brown S.G.A. McGuire A.L. Urosevic N. Chan D.T. Dogra G. Inglis T.J.J. Chakera A. Nelson D. Fisher S. Robinson B. Jaeger W.C. Armstrong S.P. Hill S.J. Pfleger K.D.G. Finsterer J. Brandau O. Stllberger C. Wallefeld W. Laing N.G. Laccone F. Hankey G.J. Chakravarty D Sboner A Nair SS Giannopolou E Li R Hennig S Mosquera JM Pauwels J Park K Kossai M Macdonald TY Fortugne J Erho N Vergara IA Ghadessi M Davicioni E Jenkins RB Palanisamy N Chen Z Nakagawa S Hirose T Bander NH Beltran H Fox AH Elemento O Rubin MA Hirose T Virnicchi G Tanigawa A Naganuma T Li R Kimura H Yokoi T Nakagawa S Bnard M Fox AH Pierron G. Coquille S. Filipovska A. Chia T. Rajappa L. Lingford J.P. Razif M.F. Thore S. Rackham O. Rackham O. Filipovska A. Filipovska A. Rackham O. Arendts G et al. Arendts G Barker A Cameron P Hill K Flicker L Haines T Lowthian J Waldron N Arendts G Redfern J Forbes A Brand C Etherton-Beer C Hill A Hunter P Nyman S Smit D. Brown S. Brown S Ball E Macdonald S Wright C McD Taylor D. Brown S Isbister G. Cassidy T Phillips M Fatovich D Duke J Edgar D Wood F. Cheng A Dwyer D Holmes M Irving L Brown S Waterer G et al. Egerton-Warburton D Gosbell AD Wadsworth A Fatovich D Richardson D. Ellis B Brown S. Fatovich D Brown S. Gillman L Jacobs I Fatovich D. Hare M Arendts G Wynaden D Leslie G. Isbister G Bawaskar H Brown S. Isbister G Page C Buckley N Fatovich D Pascu O Macdonald S Calver L Brown S. Macdonald S Arendts G Fatovich D Brown S. Macdonald S Nagree Y Fatovich D Brown S. Macdonald S Stone S Neil C van Eeden P Fatovich D Arendts G Brown S. Mitra B Jones P Fatovich D Thom O. McLay S Macdonald S. Mullins R Brown S. Nagree Y Camarda V Fatovich D Cameron P Dey I Gosbell A McCarthy S Mountain D. Nagree Y Gosbell A McCarthy S Moore K Mountain D. Stone S Bosco A Jones A Cotterell C van Eeden P Arendts G Fatovich DM Brown SGA. Stone S Phillips E Wiese M Heddle R Brown S. Jaeger W.C. Seeber R.M. Eidne K.A. and Pfleger K.D.G. 75 Title Publication Optimum blood pressure target after lacunar stroke Pro side of the argument Hypertension Founder p.Arg 446 mutation in the PDHX gene explains over half of cases with congenital lactic acidosis in Roma children Molecular Genetics and Metabolism A promoter-level mammalian expression atlas Nature Homogeneous time-resolved fluorescence-based assay to monitor extracellular signal-regulated kinase signaling in a high-throughput format Frontiers in Endocrinology Ultraviolet radiation suppresses obesity and symptoms of metabolic syndrome independently of vitamin D in mice fed a high-fat diet Diabetes Immediate-type hypersensitivity drug reactions British Journal of Clinical Pharmacology The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels PPAR Research The trojan Horse approach to tumor immunotherapy Targeting the tumor microenvironment Journal of Immunology Research Biophysical detection of diversity and bias in GPCR function Frontiers in Endocrinology Distal myosin heavy chain-7 myopathy due to the novel transition c.5566GA p.E1856K with high interfamilial cardiac variability and putative anticipation Neuromuscular Disorders Selective serotonin reuptake inhibitors and risk of cerebral bleeding Stroke The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer Nature Communications. NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies Molecular Biology of the Cell An artificial PPR scaffold for programmable RNA recognition. Molecular Biology of the Cell Analysis of the human mitochondrial transcriptome using directional deep sequencing Methods in Molecular Biology and parallel analysis of RNA ends. Synthetic biology with RNA. Synthetic Biology Nurse led care coordination trial protocol and development of a best practice resource guide for a cluster controlled clinical trial in Australian aged care facilities. Archives of gerontology and geriatrics 2014 58115-19 Response to McElwaine and Robinson. International journal of clinical practice 2014 683406 RESPOND A patient-centred program to prevent secondary falls in older people presenting to the emergency department with a fall Protocol for a multi-centre randomised controlled trial. Injury Prevention 2014 DOI 10.1136injuryprev-2014-041271 Fluid resuscitation for people with sepsis. BMJ. 2014 349g4611 Spontaneous pneumothorax a multicentre retrospective analysis of emergency treatment Intern Med J. 2014 445450-7 complications and outcomes. Clinicalresearchisapriorityforemergencymedicinebuthowdowemakeithappenanddoitwell EmergMedAustralas201426114-18 Developing a Burn Injury Severity Score BISS adding age and total body surface area burned to the Injury Severity Score ISS improves mortality concordance. Burns 201440805-813 Influenza epidemiology vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013 the Influenza Complications Alert Network. Commun Dis Intell Q Rep. 2014 382E143-9. Survey of alcohol-related presentations to Australasian Emergency Departments. Med J Aust 2014201 584-587 Management of anaphylaxis in an austere or operational environment. J Spec Oper Med. 2014 1441-5. Stroke thrombolysis remains unproven per ardua ad astra Intern Med J 2014441261-1262 Challenges in arranging interhospital transfer from a non-tertiary hospital Emergency Department in the Perth metropolitan area. Emerg Med Australas 201426567-572 Nurse Screening for Delirium in Older Patients Attending the Emergency Department. Psychosomatics 201455235-42 Scorpion envenomation. N Engl J Med. 2014 16371161559-60 Randomized controlled trial of intravenous antivenom versus placebo for Latrodectism the second Redback antivenom evaluation RAVE-II study. Ann Emerg Med 201464620-628.e2 Comparison of PIRO SOFA and MEDS scores for predicting mortality in Emergency Department Acad Emerg Med 2014211257-1263 patients with severe sepsis and septic shock. Modified TIMI risk score cannot be used to identify low-risk chest pain in the emergency Emerg Med J. 2014 314281-5 department a multicentre validation study. Sustained elevation of Resistin NGAL and IL-8 are associated with severe sepsisseptic shock in PLoS ONE 2014 910 e110678 the Emergency Department. Trainee perspectives on usefulness of the Trainee Research Requirement. Emerg Med Australas 201426392-397 Hyper-dopaminergic ballismus and respiratory dyskinesia treated with intravenous haloperidol. Emerg Med Australas. 2014 266647-8 Ant venom immunotherapy in Australia the unmet need. Med J Aust. 2014 201133-4. Quantifying the proportion of general practice and low-acuity patients in the emergency department. Med J Aust. 2013 19811612-5. Determining the true burden of general practice patients in the emergency department getting closer. Emerg Med Australas. 2013 Dec256487-90. doi 10.11111742-6723.12163. Genomic responses during acute human anaphylaxis are characterized by upregulation of innate inflammatory gene networks. PLoS One 201497e101409 Immediate-type hypersensitivity drug reactions. Br J Clin Pharmacol. 20147811-13 Molecular determinants of orexin receptor-arrestin-ubiquitin complex formation. British Journal of Pharmacology 171 364-374 HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 76 OurSupporters ADVOCATES BHP Billiton Matched Giving Program EMJC Earthmoving Paul Fisher Gavin Gillespie Komatsu lululemon athletica Australia Pty Ltd Maritime Union Australia Members at AMC Henderson EXPLORERS Atlas Iron Ltd Axis Finance Geoff Baker Angela Bennett Taryn Bettini William Busby David Edwards Euroz Foundation John Mog Gadsdon Graham Hardie Hartleys Ltd BUILDERS Dr Bob Every AO and Sheryl Every Max Lorraine Kousins Jamie Prendiville Regis Resources Ron Farris Real Estate Pty Ltd Striker Aust Pty Ltd The Helen Leech Endowment WesTrac Pty Ltd BEQUESTS Lone Ereka Alexandra Hester Bernadette Jolly Jean Kahan RESEARCH SEMINAR SUPPORT Bupa Win Hewitt Hitachi Kalamunda Toyota Peter and Lynne Leonhardt Richard Lester AM Frank Maher Mandurah Murray Mayday Club Dawn Metcalfe Jim Moore Orica Australia McCusker Charitable Foundation McCusker Charitable Foundation Carlo Orlando Anne Pickett Josh Pam Pitt Dr Dwayne Smit SMS Rental The Carcione Foundation The Jolimont Foundation The Morgan Banks Foundation Ross Williams Maritime Union Australia Members Fremantle Mass Drill Blast Pty Ltd Craig McLeish Grant Menhennett Ramsay Health Care Red Pepper Catering Rosen Australia Pty Ltd Shell Aust Darren Verwijmeren BENEFACTORS DISCOVERERS PIONEERS 77 acQuire Technology Solutions Pty Ltd ABN Foundation Action Laser Cutting Phillip Adamson Catherine Ainsworth Rebecca Altham Daniella Antonucci APEX Australia Sarina Arfuso Lyn Arnott ATC Williams Pty Ltd Noel Baker Alan Barnett Jaime Barrett Irwin Barrett-Lennard Barrick Plutonic Danielle Beck Todd Belcher Denis Belliveau Rebecca Benfield Joel Bertram Industrie Bitossi Michael Blakiston Dal Board Debra Bonney Garry Borrello BP Foundation Daren Bracewell Bevan Brendon Maurice Bridgwood Steve Brown Darren Brown Donna Brown Matthew Buckley Kathy Bunce Burrendah Social Club Taanya Burrow Andrew Burton Cameron International Corporation Carramar Resource Industries Jeffrey Carter Jon Caulfield John Cebalo Charities Aid Foundation Steve Ciavalini Vanessa Clarke Paul Colley Colliers International Sharon Collins Commonwealth Bank Ben Cooper Andrew Cross Aaron DCosta Michael Deegan DLA Piper Australia Claire Dodd Mercuri Dominic FRIENDS Leigh Donald Emma Donovan Natika Dorrius Matthys du Plessis Dual Australia Eaton Industries Pty Ltd Julie Ellery Entertainment Publications Melinda Evans Teresa Farmer Lincoln Ferguson Flinders Financial Fire Suppression Services Pty Ltd Beverley Fitzgerald Forrest Family Foundation Jeff Galloway Kate Gannon Helmut Geisner Brett Gibson Harry Glanc Jenny Glasson Global Industrial Services Global Quest Dr Joseph Glover Michael Goff IR ME Green Giacci Group Malcolm Hansen David Harwood Yukio Hayashi Margaret Haydon Luke Herbert Clive Higgins Lesley Hooper Andree Horrigan Stephen Hughes Kerry Hunter Joanne Hurrell Neil Husbands Iluka Resources Dean Irvine ISS Facility Services Peter Janus Jarrod Lloyd Thompson John Jenkins Peter Johnson Grant Johnston John Jones Richard Jones JT Day Pty Ltd Kimberley Diamond Company Ewen Koh Chee Lai Last Drop Tavern Margaret Lawrie Lockton Insurance Brokers Marty Loughrey Paul Magiatis John Mahauariki Anne-Marie Marriott Nikki Martin Kim Massey James McClements Jackson McDonald Kim McDonald Mark McIntyre Kim McLeod Wendy McMullen Shaun McRobert Melanomawa Gerard Metcalfe Metso Minerals Mid-Ship Group LLC Gareth Millard Steven Mills Simon Mills Mine Site Construction Services Jake Minear Mining and Civil Management Services Hamish Moffat Margaret Morfitt Graeme Morgan Peter Morris Robert Mule Danny Murphy Kyla Murray Kim Nairn Daryl Naismith John Nicholls Allyson-Marie Nolan Jennylee Norgard Ochre Odeum Farms Pty Ltd Offshore Plant Hire Pty Ltd Noeleen OMalley Ged Joanne Oxley OLM Parish Daniel Paull Robert Pearce Craig Pedley Jocelyn Perkins Suzanne Philpot John Poynton Peter Prendiville Garry Wendy Prendiville Nicole Prentice Prince Minerals Inc Giulia Ranelli Raywell Contracting Adam Rhodes Angela Roberts Tony Robinson Merilyn Rostant Rotary Club of Belmont Rotary Club of Dalkeith Rotary Club of Western Endeavour Rowe Scientific Pty Ltd Rachelina Santella Andrew Sarich Michelle Scamaton Fiona Schneider Mark Seares David Shephard Bruce Charles Shephard Max Shwer David Simpson Iain Simpson Carey Simpson Skilled Offshore SKILLED Group Darren Smith Prashanthan Sooriakumaran Craig Spencer Amy Steinepreis Sara Stockdale Support Vehicles Australia SVA Swagelok WA Debbie Tawton Adam Taylor Tomcat Hardchrome Engineering Pty Ltd Debbi Tomilson Transfield Worley Craig Trestrail Jules Tripodi Glen Trouchet Rob Tyson Daniel Ungvari Yvonne Valentine Bradley Van Luxemborg Coleen van Til Vero Vero Insurance Victa Golf Club Ivan Vodanovich Yunlai Wang Brian Ward Laura Ward Craig Watts Craig Wells Wentworth Plaza Hotel Elisha White Glenda Wilson Janice Wilson Chris Woolley Colin Wright James Yewers Tully Young HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 78 FinancialReports 2014 2013 Research activities 22287783 55.6 23985222 79.2 Research support 5393813 13.4 4616917 15.2 Facility expenses 3422759 8.5 264626 0.9 DepreciationandamortisationincludingFacilities 7110965 17.8 1213912 4.0 Unexpended grant income - current period c 1893008 4.7 219524 0.7 Total Expenditure 40108328 100 30300201 100 National competitive grants 6262963 18.1 5357942 16.9 International grants 207726 0.6 174990 0.6 Other grants 2972782 8.6 2813209 8.9 Commercial contracts 6465262 18.7 6069672 19.2 Government contracts 1703292 4.9 1733450 5.4 Donations and fundraising 10358331 29.9 9849455 31.1 Investment income 746863 2.2 811649 2.6 Research support - UWA 1816919 5.3 2409428 7.6 Research support - Dept of Health WA 1019527 2.9 1038756 3.3 Miscellaneous income 729576 2.1 1231152 3.8 Facility recovery income 2314323 6.7 181657 0.6 Unexpended grant income - prior periods b - 0.0 - 0.0 Total Income 34597564 100 31671360 100 2014 - The Year in Brief Income Expenditure Net Surplus 253214 26952099 Notes a The above results incorporate the statutory financial reporting results of the Harry Perkins Institute of Medical Research Inc. and the research operations conducted by researchers through the Institutes affiliation agreement with the University of Western Australia via the Centre for Medical Research. The financial results of the Institute include the operating results of its subsidiary entity Linear Clinical Research Ltd and any grants administered by the Institute. b Unexpended grant income represents grant income from prior periods which has been utilised during the current year. c Unexpended grant income for current period represents grant income received but not expended at year-end. Net operating SurplusDeficit -5510764 1371159 Capital Works Grant Income 5763978 25580940 79 FinancialReports 2014 - The Year in Brief National Competitive Grants International Grants Other Grants Commercial Contracts Government Contracts Donations and Fundraising Investment Income Research Support - UWA Research Support - Dept of Health WA Facility Recovery Income Miscellaneous Income Research Activities Research Support Facility Expenses Depreciation and amortisation including Facili Unexpended grant income - current period c Unexpected grant income - prior periods b National Competitive Grants International Grants Other Grants Commercial Contracts Government Contracts Donations and Fundraising Investment Income Research Support - UWA Research Support - Dept of Health WA Facility Recovery Income Miscellaneous Income Research Activities Research Support Facility Expenses Depreciation and amortisation including Facilities Unexpended grant income - current period c Unexpected grant income - prior periods b National Competitive Grants International Grants Other Grants Commercial Contracts Government Contracts Donations and Fundraising Investment Income Research Support - UWA Research Support - Dept of Health WA Facility Recovery Income Miscellaneous Income Research Activities Research Support Facility Expenses Depreciation and amortisation including Facilities Unexpended grant income - current period c Unexpected grant income - prior periods b Income Expenditure HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 80 The Harry Perkins Institute of Medical Research continues to achieve scientific breakthroughs that offer real hope for the patients and their families. Donors can support specific projects or give to the Perkins as a general donation. We will use your gift in the area of greatest need. 81 Howyoucanhelp-Hopestartshere However using the latest technologies to gain faster results and attracting top researchers is a constant challenge. The fact is medical research is expensive and we would not be achieving the results we are without the generous support of the community so please donate or consider leaving a bequest to the Perkins. We accept donations by post phone or online Donations over 2 are tax deductible. If you have any queries please contact Margaret Haydon Head of Marketing on 61 8 6151 0960. We are dedicated to translating our discoveries from the bench in the laboratory to the bedside offering better treatments and hopefully cures for a range of diseases. We greatly appreciate your support. Thank you for providing hope for future generations. HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Annual Report 2014 82 83 Phone 61 8 6151 0700 Fax 61 8 6151 0701 QEII Medical Centre 6 Verdun St Nedlands WA 6009 PO Box 7214 Shenton Park Western Australia 6008